<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006515</article-id><article-id pub-id-type="pmc">PMC11859484</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020148</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00148</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Bioavailability Enhancement and Formulation Technologies of Oral Mucosal Dosage Forms: A Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8663-2890</contrib-id><name><surname>B&#x000e1;cskay</surname><given-names>Ildik&#x000f3;</given-names></name></contrib><contrib contrib-type="author"><name><surname>Arany</surname><given-names>Petra</given-names></name></contrib><contrib contrib-type="author"><name><surname>Feh&#x000e9;r</surname><given-names>P&#x000e1;lma</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5835-5304</contrib-id><name><surname>J&#x000f3;zsa</surname><given-names>Liza</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0258-2599</contrib-id><name><surname>Vasv&#x000e1;ri</surname><given-names>G&#x000e1;bor</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5477-0540</contrib-id><name><surname>Nemes</surname><given-names>D&#x000e1;niel</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1326-5708</contrib-id><name><surname>Pet&#x00151;</surname><given-names>&#x000c1;gota</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7377-749X</contrib-id><name><surname>K&#x000f3;sa</surname><given-names>D&#x000f3;ra</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2123-5821</contrib-id><name><surname>Haimhoffer</surname><given-names>&#x000c1;d&#x000e1;m</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9724-0614</contrib-id><name><surname>Ujhelyi</surname><given-names>Zolt&#x000e1;n</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sinka</surname><given-names>D&#x000e1;vid</given-names></name><xref rid="c1-pharmaceutics-17-00148" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Craig</surname><given-names>Duncan</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00148">Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei k&#x000f6;r&#x000fa;t 98, 4032 Debrecen, Hungary; <email>bacskay.ildiko@pharm.unideb.hu</email> (I.B.); <email>arany.petra@euipar.unideb.hu</email> (P.A.); <email>feher.palma@pharm.unideb.hu</email> (P.F.); <email>jozsa.liza@euipar.unideb.hu</email> (L.J.); <email>vasvari.gabor@pharm.unideb.hu</email> (G.V.); <email>nemes.daniel@pharm.unideb.hu</email> (D.N.); <email>haimhoffer.adam@euipar.unideb.hu</email> (&#x000c1;.H.); <email>ujhelyi.zoltan@pharm.unideb.hu</email> (Z.U.)</aff><author-notes><corresp id="c1-pharmaceutics-17-00148"><label>*</label>Correspondence: <email>sinka.david@pharm.unideb.hu</email>; Tel.: +36-52-411-717 (ext. 58423)</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>148</elocation-id><history><date date-type="received"><day>18</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>15</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The oral mucosa is a versatile surface for drug administration, supporting both local and systemic therapies. Many active substances are effectively absorbed in the oral cavity, offering an alternative to enteral administration by bypassing the harsh gastrointestinal environment and hepatic first-pass metabolism. This has made oral mucosal drug delivery a growing area of research. Enhancing the bioavailability of active ingredients is a key focus in pharmaceutical technology, especially given the challenges of developing new drugs. Numerous strategies to improve bioavailability are compatible with oral mucosal delivery, with the unique anatomy of the oral cavity enabling specialized applications. A variety of dosage forms tailored for oral mucosal delivery meet therapeutic needs while addressing biopharmaceutical and patient compliance challenges. Proper formulation can achieve controlled release, improved bioavailability, and patient convenience. This review highlights the potential of oral mucosal drug delivery, focusing on bioavailability enhancement methods and the types and production technologies of dosage forms optimized for use in the oral cavity.</p></abstract><kwd-group><kwd>oral mucosal drug delivery</kwd><kwd>oral cavity dosage forms</kwd><kwd>bioavailability enhancement</kwd><kwd>buccal delivery</kwd></kwd-group><funding-group><award-group><funding-source>Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund</funding-source><award-id>TKP2021-EGA-18</award-id><award-id>TKP2021-EGA</award-id><award-id>2022-1.2.2-T&#x000c9;T-IPARI-UZ-2022-00006</award-id></award-group><funding-statement>This research was funded by TKP2021-EGA-18, implemented with support provided by the Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-EGA funding scheme, and by 2022-1.2.2-T&#x000c9;T-IPARI-UZ-2022-00006 for the common research and development of different prototypes containing natural herb extracts for industrial utilization.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00148"><title>1. Introduction</title><p>Oral medication is considered the primary therapeutic route because of its patient convenience, safety, and simplicity. Manufacturing traditional oral dosage forms can also be considered easy and cost-effective compared to others. However, the environment of the gastrointestinal (GI) tract is challenging for both the pharmacon and drug delivery systems because of the extreme pH conditions, different types of intestinal cells, and the presence of digestive enzymes, food, and intestinal bacteria [<xref rid="B1-pharmaceutics-17-00148" ref-type="bibr">1</xref>].</p><p>Medicines used in the oral cavity are among the oldest therapeutic tools. Originally, they were intended for mostly local treatment, but the oral mucosa provides an excellent absorption surface for a wide variety of active substances, which cause a systemic effect when entering the bloodstream.</p><p>Oral mucosal drug delivery dosage forms have most of the advantages of oral administration, and compliance is even higher in the case of some patient groups like children, elderly people, and patients with swallowing difficulties [<xref rid="B2-pharmaceutics-17-00148" ref-type="bibr">2</xref>].</p><p>Because of the numerous advantages and possibilities, most importantly, easy, convenient, and safe use, quick pharmacological responses, and the opportunity to administer a wider range of pharmacons, oral mucosal drug delivery has been an important topic in academic and applied science for years. We found several examples of articles that summarized the results described in this field from a biological&#x02013;physiological [<xref rid="B3-pharmaceutics-17-00148" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-17-00148" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-17-00148" ref-type="bibr">5</xref>] or technological formulation [<xref rid="B6-pharmaceutics-17-00148" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-17-00148" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-17-00148" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-17-00148" ref-type="bibr">9</xref>] point of view. The purpose of this review is to briefly present the currently most important technological opportunities, focusing on biopharmaceutics and bioavailability.</p></sec><sec id="sec2-pharmaceutics-17-00148"><title>2. Bioavailability from the Oral Cavity</title><sec id="sec2dot1-pharmaceutics-17-00148"><title>2.1. Oral Cavity and the Oral Mucous Membrane</title><p>The oral cavity is the first receiving part of the gastrointestinal tract. It extends from the mouth opening to the pharynx and is bounded by the cheeks at the side, the floor of the mouth at the bottom, and the hard and soft palates at the top. The teeth are located in the front section, and the tongue is in the bottom (<xref rid="pharmaceutics-17-00148-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B10-pharmaceutics-17-00148" ref-type="bibr">10</xref>]. Several salivary glands are located in the oral cavity, producing saliva and mucus [<xref rid="B11-pharmaceutics-17-00148" ref-type="bibr">11</xref>]; furthermore, special neuroanatomical structures, namely taste buds, form part of the oral papillae [<xref rid="B12-pharmaceutics-17-00148" ref-type="bibr">12</xref>].</p><p>The mucous membrane or mucosa is a membrane that covers the surface of internal organs and lines the body cavities. It is covered with mucus [<xref rid="B13-pharmaceutics-17-00148" ref-type="bibr">13</xref>]. The main role of the human body mucosa besides isolation is transport and, to a lesser extent, immunological protection against pathogens. The oral mucous membrane consists of the buccal, sublingual, gingival, palatal, and labial mucosa [<xref rid="B14-pharmaceutics-17-00148" ref-type="bibr">14</xref>].</p><p>The oral cavity, due to its complex anatomical structure, has several functions. The most important is its role in feeding. The food is uptaken, masticated, mixed with saliva, formed into a bolus, and transported to the further parts of the GI tract in the mouth. The digestive process also begins in the oral cavity by the enzymes of the saliva, mainly the amylase, which starts to break down carbohydrates. In addition, being connected to the pharynx, the oral cavity also facilitates breathing. It has an important role in communication, modulating the sound formed in the larynx [<xref rid="B15-pharmaceutics-17-00148" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-00148" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-17-00148" ref-type="bibr">17</xref>].</p></sec><sec id="sec2dot2-pharmaceutics-17-00148"><title>2.2. Absorption from the Oral Cavity</title><p>Besides the oral drug delivery route, considered the primary route in pharmaceutical development, different mucous membranes of the human body also have significance in pharmacotherapy [<xref rid="B18-pharmaceutics-17-00148" ref-type="bibr">18</xref>]. The oral cavity is lined by the oral mucosa, which is structurally inhomogenous depending on the function. The upper layer consists of epithelial cells, and the basement membrane, lamina propria, and submucosa are located below that. In these layers, the oral mucosa contains different receptors, like taste buds and smaller salivary glands [<xref rid="B19-pharmaceutics-17-00148" ref-type="bibr">19</xref>].</p><p>Enteral drug delivery is considered the primary route of pharmacon intake, and oral mucosal delivery shares its main advantages. Aside from the high patient compliance, relatively low costs, and administration not requiring special knowledge, it also has additional advantages. These forms of medication are easier to use for patients with swallowing difficulties, but, in many cases, the fact that they do not require liquid for intake is also more convenient [<xref rid="B20-pharmaceutics-17-00148" ref-type="bibr">20</xref>]. Pharmacons do not degrade in the environment of the GI tract, but by bypassing the hepatic first-pass metabolism, they acquire direct access to the systemic circulation, which means a shorter response time. The oral cavity also allows the use of a wide range of dosage forms [<xref rid="B4-pharmaceutics-17-00148" ref-type="bibr">4</xref>].</p><p>Adequate taste masking and the avoidance of irritation can be considered the biggest challenges in oral mucosal drug delivery. The taste is formed when the substance dissolves in saliva and then contacts the taste buds. Excessive consumption of active substances is toxic to the body in a significant proportion of cases, and the unpleasant bitter taste is an evolutionary defense mechanism against it. The unpleasant taste leads to lower patient compliance and is considered the most important obstacle to therapy in pediatrics. The conventional way to eliminate the problem is taste masking, the sweetening of the preparation with sugar, artificial sweeteners, or various extracts and aromas. Each of these has advantages and disadvantages, such as increased carbohydrate intake or long-term health damage, and is usually used in combination. Modern methods for flavor enhancement include, for example, the use of ion-exchange resin, solid dispersion, spray drying, microencapsulation, and inclusion complexes. However, these technologies are usually more expensive and require more excipients and special formulating conditions. Both approaches (sweeteners and advanced technological taste masking) aim to enhance the palatability of pharmaceutical products by reducement of the sensory impact of bitter drugs and improvement in the patient&#x02019;s experience. They can be combined for a complementary effect, where sweeteners provide a basic layer of taste masking and eliminate any residual bitterness in tandem with advanced technological methods. The effectiveness of different flavor masking options or their combinations and the specific excipients used can vary from composition to composition, and the subjectivity of taste perception makes their evaluation even more difficult [<xref rid="B21-pharmaceutics-17-00148" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-17-00148" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-17-00148" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-17-00148" ref-type="bibr">24</xref>].</p><p>The volume capacity of the oral cavity (approximately 111 cm<sup>3</sup> on average [<xref rid="B25-pharmaceutics-17-00148" ref-type="bibr">25</xref>]) limits the pharmacon dose. Beyond that, the possibility of swallowing, the absorption difficulties due to the physical&#x02013;chemical properties of the active ingredient, or stability problems are also potential limiting factors [<xref rid="B26-pharmaceutics-17-00148" ref-type="bibr">26</xref>].</p><p>Drug delivery systems administered in the oral cavity can aim for either (a) local or (b) systemic effects; in the latter case, the pharmacon has to be absorbed through the buccal or sublingual mucosa and transported to the submucosa containing blood vessels [<xref rid="B27-pharmaceutics-17-00148" ref-type="bibr">27</xref>]. The factors affecting absorption primarily are the fluid volume, pH value, enzyme activity, penetration through the mucosa cell barriers, and cell turnover.</p><p>Saliva has the most important role in creating the environment of the mouth. It is a thin, hydrophilic liquid secreted by three major and several smaller salivary glands. Saliva lubricates the oral cavity, facilitating swallowing and preventing the demineralization of the teeth. Furthermore, saliva maintains oral enzyme activity, which is part of the digestion, and the oral pH, regulating microbial homeostasis. Saliva production highly depends on several factors, like the time of day or the nature and intensity of stimulation. These factors influence the amount, pH, and composition of the produced saliva [<xref rid="B28-pharmaceutics-17-00148" ref-type="bibr">28</xref>].</p><p>Compared to the orally administered formulations absorbed intestinally, the fluid volume is significantly lower in the mouth, about 1.1 mL, which makes the dissolution and permeation difficult. In addition, elevated saliva production can lead to &#x0201c;saliva wash out&#x0201d;, a phenomenon related to premature swallowing of the product, resulting in inadequate pharmacon liberation and absorption. On the other hand, saliva is less viscous compared to the other gastrointestinal fluids; it contains organic and inorganic components only in 1% of them. The pH value is between 5.5 and 7, which is a much more friendly and steady environment than the more extreme ranges in the further parts of the GI tract. The enzymatic breakdown of drugs is an important problem regarding the whole digestive system, but the enzyme activity of the saliva is much lower than other secretions. This can be of particular importance in the delivery of peptide-type active ingredients since mostly carbohydrates are digested in the oral cavity, and proteases are less present [<xref rid="B29-pharmaceutics-17-00148" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00148" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-17-00148" ref-type="bibr">31</xref>].</p><p>The parameters of different GI secretions are compared in <xref rid="pharmaceutics-17-00148-t001" ref-type="table">Table 1</xref>.</p><p>The mucus of the oral mucosa consists mainly of proteins and carbohydrates. Its most important macromolecular component is mucin, a glycoprotein capable of forming a network structure and bonding to the surface of the epithelial cells as a gel layer, exerting a lubricating effect [<xref rid="B35-pharmaceutics-17-00148" ref-type="bibr">35</xref>].</p><p>The thickness and structure of the oral mucosa vary, strongly depending on the function of the given part of the oral cavity. The epithelia is keratinized where it is more exposed to mechanical effects, which means better barrier function at the same time. Epithelia contain different lipids, which make them less permeable to water. The buccal and sublingual mucosa are non-keratinized; therefore, the absorption from it is significantly better than from the rest of the oral cavity and is many times that of the absorption from the skin, as can be seen in <xref rid="pharmaceutics-17-00148-t002" ref-type="table">Table 2</xref> [<xref rid="B36-pharmaceutics-17-00148" ref-type="bibr">36</xref>].</p><p>Both keratinized and non-keratinized mucosa contain membrane-coating granules, which empty their content into the intercellular space to ensure epithelial cohesion, which is a barrier to most penetrating substances [<xref rid="B38-pharmaceutics-17-00148" ref-type="bibr">38</xref>]. Absorption is better in cell cultures that do not contain membrane-coating granules [<xref rid="B39-pharmaceutics-17-00148" ref-type="bibr">39</xref>].</p><p>Permeation through the mucous membrane can occur by passive diffusion, carrier-mediated active transport, or other special methods like facilitated diffusion or specialized transport mechanisms. According to studies, absorption from the oral cavity is mainly a passive process, paracellular or transcellular. The affected spaces, namely the paracellular space and the cytoplasm, are hydrophilic media, and this favors water-soluble drugs over lipophilic ones; meanwhile, the lipophilic cell membranes of the transcellular route are more passable for apolar molecules [<xref rid="B40-pharmaceutics-17-00148" ref-type="bibr">40</xref>]. Several studies have described carrier-mediated-active transport of some pharmacons through the oral mucosa [<xref rid="B41-pharmaceutics-17-00148" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-17-00148" ref-type="bibr">42</xref>]. In this case, the mediating carriers can be uptake or efflux transporters, proteins located on the apical surface of the epithelial cells. They require energy from ATP breakdown or are paired with a co-transport mechanism of a counterion [<xref rid="B43-pharmaceutics-17-00148" ref-type="bibr">43</xref>].</p><p>Cell replenishment of the oral mucosa is 14&#x02013;21 days, a shorter period than the 20&#x02013;30 days cell turnover of the skin [<xref rid="B44-pharmaceutics-17-00148" ref-type="bibr">44</xref>] because of the high functional demand in the oral cavity. This factor can also play a role in absorption from the mouth [<xref rid="B13-pharmaceutics-17-00148" ref-type="bibr">13</xref>].</p></sec><sec id="sec2dot3-pharmaceutics-17-00148"><title>2.3. Bioavailability Enhancement Through the Oral Mucosa</title><p>There are several options for bioavailability enhancement from the oral cavity; some of them are used in marketed products, and other methods are frequent topics of research (<xref rid="pharmaceutics-17-00148-t003" ref-type="table">Table 3</xref> and <xref rid="pharmaceutics-17-00148-t004" ref-type="table">Table 4</xref>).</p><p>Speaking of bioavailability enhancement on mucous membranes, it is worth mentioning the phenomenon of mucoadhesion, as well as the formulations that take advantage of this. During mucoadhesion, attractive forces are established between a biological material and the mucous membrane or mucus. In the first contact stage, contact occurs at the border of the mucoadhesive and the mucosa. In the second consolidation stage, different interactions take place, strengthening the joint and prolonging the adhesion [<xref rid="B69-pharmaceutics-17-00148" ref-type="bibr">69</xref>]. There are several theories to describe the process of mucoadhesion, among which the adhesion theory and the diffusion-interlocking theory can be highlighted. According to the adhesion theory, the connection between the adhesive polymer and the mucosa is provided by primary and secondary bonds. The chemisorption is based on ionic, covalent, and metallic bonds [<xref rid="B70-pharmaceutics-17-00148" ref-type="bibr">70</xref>]. According to diffusion-interlocking theory, a two-way interdiffusion occurs between the mucoadhesive polymer chains and the glycoprotein network of the mucosa [<xref rid="B71-pharmaceutics-17-00148" ref-type="bibr">71</xref>].</p><p>Mucoadhesive drug delivery systems are based on hydrophilic polymer macromolecules. Their essential properties are their negative charge potential and hydrogen bond-forming groups in their structure. Hydroxyl, carboxyl, and amine groups are the most favorable. Adhesion is formed by wetting [<xref rid="B72-pharmaceutics-17-00148" ref-type="bibr">72</xref>]. Mucoadhesive polymers are divided into two generations [<xref rid="B73-pharmaceutics-17-00148" ref-type="bibr">73</xref>]. First-generation mucoadhesives are either anionic, cationic, or non-ionic materials. Anionic polymers are the most widely used of them, like polyacrylic acid [<xref rid="B74-pharmaceutics-17-00148" ref-type="bibr">74</xref>] or sodium carboxymethyl-cellulose [<xref rid="B75-pharmaceutics-17-00148" ref-type="bibr">75</xref>]. The most common of the cationic substances is chitosan, which can be produced by chitin deacetylation. Chitosan has good biocompatibility and biodegradability properties and can be easily modified by adding different chemical groups into the form that best suits the purpose of use [<xref rid="B76-pharmaceutics-17-00148" ref-type="bibr">76</xref>]. However, chitosan has the disadvantages of batch-to-batch variability, stability problems, immunogenic and allergenic potential, environmental sensitivity, and the possibility of interactions with drugs [<xref rid="B77-pharmaceutics-17-00148" ref-type="bibr">77</xref>]. First-generation mucoadhesive polymers share the benefits of easy use and low toxicity [<xref rid="B36-pharmaceutics-17-00148" ref-type="bibr">36</xref>].</p><p>Second-generation mucoadhesive materials are also commonly called cytoadhesive polymers because they bind directly to the surface of the mucous membrane, enabling more precise drug delivery due to the different carbohydrate and protein compositions of the mucous membrane in different areas. Lectins are natural polymers that have a basic role in biological recognition. After binding to the mucosa, lectins can remain on the cell surface, or in the case of receptor-mediated adhesion, they can be internalized by endocytosis. Although lectins have advantages in terms of both targeting and binding, their use is limited by their toxic or immunogenic properties, in addition to the ability of lectin-induced antibodies to interfere with mucoadhesion [<xref rid="B78-pharmaceutics-17-00148" ref-type="bibr">78</xref>]. Thiomers are thiolated polymers produced via the modification of materials like polyacrylates, chitosan, or deacetylated gellan gum. Thiol groups form covalent bonds with the deeper, cysteine-rich layers of mucin. The covalent bonds formed by second-generation mucoadhesives are less sensitive to the changes in ionic strength or pH, although thiol groups can be oxidized at pH values below 5, which can lead to a destabilized thiomer structure [<xref rid="B79-pharmaceutics-17-00148" ref-type="bibr">79</xref>,<xref rid="B80-pharmaceutics-17-00148" ref-type="bibr">80</xref>].</p><p>The other possibility for increasing bioavailability is the use of penetration enhancers, which are common in a wide range of dosage forms. Drug permeability from the oral mucosa can also be increased with these excipients, such as bile salts, like sodium deoxycholate or sodium taurocholate; fatty acids, namely sodium laurate, sodium myristate, and oleic acid; and surfactants, namely sucrose laurate, cyclodextrins, chelators, ethanol, propylene glycol, and chitosan, which are the most commonly used materials [<xref rid="B81-pharmaceutics-17-00148" ref-type="bibr">81</xref>].</p><p>In the case of some formulations, bioavailability enhancement is achieved by the possibly fastest disintegration of the product and almost immediate liberation of the pharmacon, often in a few seconds after administration, in contrast to the prolonged retention time of mucoadhesive systems. All this is in the relatively low liquid volume characteristic of the oral cavity [<xref rid="B82-pharmaceutics-17-00148" ref-type="bibr">82</xref>].</p><p>Although enzyme activity is significantly lower in the saliva than in the other parts of the GI tract, it still can damage the active ingredients. Pharmacon degradation can be decreased by the incorporation of enzyme inhibitor components, with aprotinin, bestatin, and puromycin being the most commonly used [<xref rid="B83-pharmaceutics-17-00148" ref-type="bibr">83</xref>,<xref rid="B84-pharmaceutics-17-00148" ref-type="bibr">84</xref>]. Protease inhibition also enhances the absorption and bioavailability of peptide and protein-type drugs, which is a considerable advantage of oral mucosal drug delivery over enteral drug administration [<xref rid="B85-pharmaceutics-17-00148" ref-type="bibr">85</xref>].</p><p>There are several possibilities to modify active ingredients to increase their bioavailability. Prodrugs are inactive forms of the pharmacon that transform to the parent drug during absorption or metabolism [<xref rid="B86-pharmaceutics-17-00148" ref-type="bibr">86</xref>]. The buccal bioavailability of morphine proved to be increased in vivo by the use of morphine-esther prodrugs [<xref rid="B55-pharmaceutics-17-00148" ref-type="bibr">55</xref>]. Particle size reduction also enhances solubility and permeability in general, and studies can be found of buccal bioavailability increases with this method for different active ingredients [<xref rid="B87-pharmaceutics-17-00148" ref-type="bibr">87</xref>,<xref rid="B88-pharmaceutics-17-00148" ref-type="bibr">88</xref>]. By modifying the lipophilicity of the molecules, the permeation through the lipid-rich membrane of the mucosa can be improved [<xref rid="B89-pharmaceutics-17-00148" ref-type="bibr">89</xref>].</p><p>Different carrier formulations like nanoparticles and liposomes encapsulate drug molecules, protecting them and providing increased absorption. In addition, they can achieve controlled, prolonged release of the active ingredient, which can further improve bioavailability [<xref rid="B90-pharmaceutics-17-00148" ref-type="bibr">90</xref>]. Pullulan-based particles were found to have a long retention time and sustained pharmacon release profile, leading to better delivery to less accessible regions, as well as reduced irritation and improved patient compliance [<xref rid="B91-pharmaceutics-17-00148" ref-type="bibr">91</xref>].</p><p>Micro- and nanosized particles enable faster and increased absorption from the oral mucosa. The various types of particles have different formulation methods and advantages. Liposomes improve the bioavailability of pharmacons with poor water solubility and mucosal permeability from solid forms and also enhance the stability of active ingredients, which is an important advantage in phytopharmacon therapy [<xref rid="B65-pharmaceutics-17-00148" ref-type="bibr">65</xref>]. Microparticles based on suitable polymers have mucoadhesive properties, elongating the retention time on the surface of the oral mucosa [<xref rid="B92-pharmaceutics-17-00148" ref-type="bibr">92</xref>]. The proper polymer blend of polyglycolic acid derivatives shows suitable adhesive properties not only to the mucosa but also to the dental surface, which leads to an elongated and more effective antimicrobial treatment [<xref rid="B93-pharmaceutics-17-00148" ref-type="bibr">93</xref>]. Permeability improvement and enhanced systemic effects can be achieved with solid lipid nanoparticles [<xref rid="B94-pharmaceutics-17-00148" ref-type="bibr">94</xref>] or polystyrene nanoparticles [<xref rid="B95-pharmaceutics-17-00148" ref-type="bibr">95</xref>], which are absorbed through the mucous membrane cells.</p><p>Fast-dissolving particles formulated by freeze-drying [<xref rid="B96-pharmaceutics-17-00148" ref-type="bibr">96</xref>], possibly combined and stabilized with beta-cyclodextrins [<xref rid="B97-pharmaceutics-17-00148" ref-type="bibr">97</xref>], are able to significantly increase solubility (even with the minimal amount of fluid in the oral cavity) and, therefore, plasma concentration.</p><p>Micro- and nanoparticles can be incorporated into most of the dosage forms intended for oral mucosal drug delivery. Aqueous suspensions, aerosols, or ointments are the easiest ways to use them. Their small size results in more convenient use for the patient, but on the other hand, the lower predictability than unit dose forms, in terms of the administered pharmacon amount, can be a disadvantage.</p></sec></sec><sec id="sec3-pharmaceutics-17-00148"><title>3. Oral Mucosal Drug Delivery Dosage Forms and Formulation Technologies</title><sec id="sec3dot1-pharmaceutics-17-00148"><title>3.1. Liquid</title><p>Liquid dosage forms applied in the oral cavity are typically solutions or suspensions in a proper (aqueous) vehicle. Their use is determined basically by their short retention time on the oral mucosa. Also, targeted delivery is often problematic to achieve, and absorption is difficult to control. Accordingly, the products are primarily antibacterial mouthwashes and mouth fresheners intended for local use, like Listerine or Curasept [<xref rid="B98-pharmaceutics-17-00148" ref-type="bibr">98</xref>,<xref rid="B99-pharmaceutics-17-00148" ref-type="bibr">99</xref>].</p><p>Regarding systemic therapy, with a significantly different and wider range of treatment possibilities, oral liquid drug delivery systems (OLDDSs) and oral liquid controlled release (OLCR) have gained attention in recent years because of their numerous advantages, like their easy administration and good spreadability [<xref rid="B100-pharmaceutics-17-00148" ref-type="bibr">100</xref>]. Iontophoretic technology is a promising method for improving absorption and systemic treatment. Iontophoresis is based on electrophoresis, electroosmosis, and electropermeabilization and is found to be safe and effective in the case of buccal prilocaine, lidocaine, naltrexone, sumatriptan, and atenolol delivery, among other active ingredients [<xref rid="B101-pharmaceutics-17-00148" ref-type="bibr">101</xref>].</p></sec><sec id="sec3dot2-pharmaceutics-17-00148"><title>3.2. Semi-Solid</title><p>The semi-solid dosage forms used in the oral cavity include gels, creams, and ointments, which are applied topically to exert a local or systemic effect. The base of the formulation is usually some type of polymer. The most obvious is the use of hydrogels since polymers that can hydrate in the aqueous environment of the oral cavity can trap the active ingredient and prolong its release during diffusion or erosion. Semi-solid formulations can be applied with the fingers or a suitable application device, which can facilitate placement in the right spot and easy spreading on the mucous membrane. In many cases, their use means a better feeling for the patient compared to solid drug forms [<xref rid="B102-pharmaceutics-17-00148" ref-type="bibr">102</xref>]. At the same time, the amount of pharmacon delivered is in a much wider range compared to unit dose formulations, and semi-solid systems spend a short retention time in the oral cavity. The latter problem can be eliminated by using bioadhesive polymers in the composition [<xref rid="B103-pharmaceutics-17-00148" ref-type="bibr">103</xref>]. The commercially available products are mostly local analgesics like Xylonor or mouth moisturizers like OralBalance.</p></sec><sec id="sec3dot3-pharmaceutics-17-00148"><title>3.3. Solid</title><p>Solid dosage forms are the most common, considering their advantages in terms of production, stability, and application. They are also the most diverse group of oral mucosal medications regarding formulation technology methods.</p><p><bold>Medical lozenges</bold> are flavored, often sugar-based formulations designed to slow disintegration in the oral cavity. The pharmacon is released directly to the mucosa of the mouth and the throat from the lozenges, which can be divided into hard and soft lozenges. Medical lozenge formulation technologies include melting and direct compression. Their key characteristic is their slow pharmacon release. Among the disadvantages of medical lozenges, we can find the danger of overuse, especially for children, as well as risks regarding premature swallowing in the case of some formulations. Furthermore, lozenges generally spend circa 30 min at most in the oral cavity, which limits the incorporated pharmacon quantity, and the disintegration depends on the patient (increased saliva production, chewing). Hard and soft lozenges are among the oldest forms of medicine used in the oral cavity, primarily for local therapy, mostly for sore throats, local anesthesia, and disinfection; less often with pharmacons that enter the systemic circulation, such as nicotine, cough suppressants, and vitamin preparations. The primary methods for the formulation of medical lozenges are direct compression or melting and molding processes. During direct compression, the active ingredients and auxiliary materials, including polymers and sweeteners in the form of powder or granules, are pressed directly. Melting and molding are based on the precise temperature control of the heated base materials, mostly polymers, sugar, and binding agents, forming a homogenous mass. Then, the APIs are added, and the liquid is poured into a properly designed mold, ensuring precise dosing and consistency in distribution. In the mold, the lozenges are cooled to solidify at room temperature or in refrigerated chambers [<xref rid="B104-pharmaceutics-17-00148" ref-type="bibr">104</xref>]. They are not the focus of modern drug delivery system research despite the fact that studies found them a promising dosage form in the bioavailability enhancement of drugs like resveratrol and also in combination technology with self-emulsifying systems [<xref rid="B105-pharmaceutics-17-00148" ref-type="bibr">105</xref>,<xref rid="B106-pharmaceutics-17-00148" ref-type="bibr">106</xref>,<xref rid="B107-pharmaceutics-17-00148" ref-type="bibr">107</xref>,<xref rid="B108-pharmaceutics-17-00148" ref-type="bibr">108</xref>]. Several popular medical lozenges are available commercially, like the antiseptic Strepsils or the smoking cessation aid Nicorette.</p><p><bold>Medicated chewing gum</bold> is an extended-release dosage form with similarities to lozenges. The main difference is that chewing gums contain a water-insoluble base like latex, plastics, solid paraffin, or bees&#x02019; wax, which is not dissolved during the application. They are manufactured by direct compression or fusion. Chewing gum products are most commonly used in therapies for motion sickness (Travelgum), smoking (Nicorette), pain (Aspergum), and nausea (Biodramina) [<xref rid="B109-pharmaceutics-17-00148" ref-type="bibr">109</xref>]. Unlike lozenges, chewing gum can cause stress on the jaws, leading to joint and muscle disorders in the long run. Also, they require a wider selection of different excipient types for proper formulation, sometimes pairing with more complicated manufacturing methods, although the most commonly used techniques are direct compression and melting and molding [<xref rid="B110-pharmaceutics-17-00148" ref-type="bibr">110</xref>].</p><p>For the formulation of <bold>buccal matrix tablets</bold>, a bioadhesive polymer, like carbopol, hydroxypropyl methylcellulose, modified starch, sodium alginate, or polyacrylic acid, is incorporated into the matrix containing the pharmacon and the excipients. The tablet adheres to the mucous membrane of the oral cavity and, in accordance with the general properties of matrix tablets, enables a prolonged release of the active ingredient [<xref rid="B111-pharmaceutics-17-00148" ref-type="bibr">111</xref>]. Matrix tablet structures can be various; by incorporating an inert or impermeable layer, the release and loss of the active ingredient in the direction of the oral cavity can be prevented, allowing only pharmacon release towards the mucous membrane. Buccal mucoadhesive matrix tablets can be a proper vehicle system for different types of drugs, including peptides such as insulin, calcitonin, and Glucagon-like peptide 1 [<xref rid="B112-pharmaceutics-17-00148" ref-type="bibr">112</xref>]. A further advantage of matrix tablets is that they can be formulated using the equipment for traditional tablet manufacturing by methods like direct compression [<xref rid="B113-pharmaceutics-17-00148" ref-type="bibr">113</xref>] or dry granulation [<xref rid="B114-pharmaceutics-17-00148" ref-type="bibr">114</xref>]; the function of the preparation is based on the selection of excipients. Striant is a buccal matrix system designed for controlled and sustained testosterone delivery.</p><p><bold>Orodispersible tablets (ODT)</bold> are based on a porous or soft matrix. This technology, in contrast to other solid forms of oral mucosal drug delivery, targets rapid disintegration and dissolution in the mouth; therefore, the goal during production is to maximize the porosity of the tablet matrix. The excipients used during the formulation can promote disintegration and increase or accelerate water solubility. By these methods, we can ensure the rapid penetration of water into the tablet matrix, the short disintegration time of the system, and the quick dissolution of the active ingredient. Moreover, the formulation should provide this without requiring water for tablet intake. Co-processed excipients are widely used for the formulation of ODTs. They are combinations of two or more excipients designed to enhance physical properties, mostly flowability, compressibility, and rapid disintegration. They are produced by spray drying, wet granulation, or co-crystallization. The most popular products are F-Melt<sup>&#x000ae;</sup> (Fuji Chemical Industries Co., Ltd., Toyama, Japan) (carbohydrates and disintegrants), Ludiflash<sup>&#x000ae;</sup> (BASF Pharma, Ludwigshafen, Germany) (mannitol, crospovidone, and polyvinyl acetate), StarLac<sup>&#x000ae;</sup> (MEGGLE Pharma, Wasserburg am Inn, Germany) (lactose and starch), Prosolv<sup>&#x000ae;</sup> (JRS PHARMA, Rosenberg, Germany) (microcrystalline cellulose and colloidal silicon dioxide), and Parteck<sup>&#x000ae;</sup> variations (Merck KGaA, Darmstadt, Germany) [<xref rid="B115-pharmaceutics-17-00148" ref-type="bibr">115</xref>]. ODTs are beneficial for patient groups with swallowing difficulties, and the risk of suffocation can also be avoided with them. At the same time, a disadvantage is their hygroscopic nature, which may require special packaging, as well as the slightly more complicated and expensive technology involved in their production [<xref rid="B116-pharmaceutics-17-00148" ref-type="bibr">116</xref>,<xref rid="B117-pharmaceutics-17-00148" ref-type="bibr">117</xref>,<xref rid="B118-pharmaceutics-17-00148" ref-type="bibr">118</xref>].</p><p>There are several technological options for the production of ODTs, as can be seen in <xref rid="pharmaceutics-17-00148-f002" ref-type="fig">Figure 2</xref>, of which the direct pressing process is the most simple and economical, similar to traditional tablets. The selection of excipients that ensure the appropriate porosity is crucial. The most commonly used disintegrant materials are different types of starch or starch derivatives, like sodium starch glycolate and pregelatinized starch. Microcrystalline cellulose and mannitol are also often used [<xref rid="B10-pharmaceutics-17-00148" ref-type="bibr">10</xref>,<xref rid="B119-pharmaceutics-17-00148" ref-type="bibr">119</xref>,<xref rid="B120-pharmaceutics-17-00148" ref-type="bibr">120</xref>].</p><p>The porosity of the tablets produced by direct pressing can be further increased by <bold>sublimation</bold> technology. In this process, volatile components (e.g., ammonium carbonate, ammonium bicarbonate, camphor, benzoic acid, naphthalene, urea, urethane, thymol, phthalic anhydride) are incorporated into the matrix [<xref rid="B121-pharmaceutics-17-00148" ref-type="bibr">121</xref>]. These additives sublimate later, leaving numerous pores and channels in the tablet. Through these openings, the solvent can more easily and rapidly enter the tablet, and the disintegration time can be shortened to 10&#x02013;20 s [<xref rid="B122-pharmaceutics-17-00148" ref-type="bibr">122</xref>]. Nimulid-MD for pain and inflammation is manufactured using this method.</p><p>During <bold>lyophilization</bold>, in the first step, the temperature of the solvent is decreased below the freezing point, and the system solidifies. Then, in the second step, the solvent sublimates from the system at low pressure and increasing temperature. The remaining solid material has an amorphous structure and is extremely porous, which makes its rapid dissolution possible [<xref rid="B123-pharmaceutics-17-00148" ref-type="bibr">123</xref>,<xref rid="B124-pharmaceutics-17-00148" ref-type="bibr">124</xref>]. The pharmacon can also be placed into an aqueous solution of the carrier system in the prepared blister pack. The mixture freezes while passing through a liquid nitrogen tunnel. After rapid and efficient low-temperature freezing, the blisters are freeze-dried at low pressure, and then the packaging is closed after the solvent has evaporated [<xref rid="B81-pharmaceutics-17-00148" ref-type="bibr">81</xref>]. The technology is expensive, but it makes the incorporation of heat-sensitive substances possible [<xref rid="B125-pharmaceutics-17-00148" ref-type="bibr">125</xref>]. The formulation of Claritin RediTabs, an antiallergic medication based on Zydis Technology, using the liophilization method.</p><p>Two types of <bold>molding methods</bold> are distinguished. In compression molding, the powder mixture is placed in a water&#x02013;alcohol solvent, and this wet mass is pressed into a mold under low pressure. Then, the solvent is air-dried, and the remaining tablet is solid and porous. During the heated molding method, a suspension made from a mixture of the active ingredient, some type of sugar (e.g., mannitol, sorbitol, lactose), and agar is poured into the cavities of the prepared blister pack, where the agar solidifies and forms a gel structure. The product is dried under vacuum [<xref rid="B126-pharmaceutics-17-00148" ref-type="bibr">126</xref>]. Molding is used in the formulation of Panadol ActiFast ODT for pain relief and fever reduction.</p><p><bold>Spray drying</bold> breaks down the solution or suspension into small droplets using a spray head, increasing the surface area so that the solvent can be quickly removed in the flow of drying air, and the resulting steam forms a protective layer around the particles. Heat-sensitive materials can also be processed with this technology. The dried particles are porous and suitable for compression. Formulations with spray-dried excipient bases have proven to have enhanced drug release in comparison with directly compressed products, such as valdecoxib and metoclopramide [<xref rid="B127-pharmaceutics-17-00148" ref-type="bibr">127</xref>]. The spray drying technique is used for the production of Maxalt-MLT for acute migraine treatment.</p><p><bold>The cotton candy method</bold> is based on saccharides and polysaccharides (e.g., polymaltodextrin and polydextrose) that are quickly melted at 180&#x02013;260 &#x000b0;C and formed into sugar fibers using a spin-like device. Then, the fibers are ground and mixed with active ingredients and excipients. This mixture is pressed into a tablet, resulting in appropriate mechanical and structural characteristics [<xref rid="B128-pharmaceutics-17-00148" ref-type="bibr">128</xref>]. FlashDose technology incorporates the cotton candy method and is used for the production of Nurofen Meltlet, a fast-acting pain relief.</p><p>It is possible to create a porous tablet matrix by building layers of the product on top of each other using <bold>3D printing</bold> technology. The tablets produced this way disintegrate in the oral cavity in a few seconds, but their production is slow and expensive compared to other technologies. 3D-printed tablets containing various active ingredients are heavily researched, and the results of technologies like selective laser sintering and fused deposition modeling are promising. Inside the selective laser sintering machine, a thin layer of powder is spread. A computer-controlled laser selectively scans it, heating specific areas to a temperature where the particles melt together. After one layer is completed, the building platform slightly descends, and a new layer of powder is spread. The process is repeated layer by layer until the entire product is formed. Fused deposition modeling is also based on layer-by-layer printing on a descending platform, but this technology uses a filament containing APIs fed into a heated nozzle, which melts and extrudes it on the building platform according to the digital design [<xref rid="B129-pharmaceutics-17-00148" ref-type="bibr">129</xref>,<xref rid="B130-pharmaceutics-17-00148" ref-type="bibr">130</xref>]. Only one marketed 3D-printed ODT product can be found, Spritam, for the treatment of epilepsy, using ZipDose technology [<xref rid="B131-pharmaceutics-17-00148" ref-type="bibr">131</xref>].</p><p>Bioadhesive <bold>buccal discs</bold> are similar to tablets in numerous properties but thinner and flatter than others, and their shape can be adjusted according to the application in the buccal cavity. Based on the tests, they are less irritating, easier and more comfortable to use, and do not cause a dry mouth [<xref rid="B132-pharmaceutics-17-00148" ref-type="bibr">132</xref>,<xref rid="B133-pharmaceutics-17-00148" ref-type="bibr">133</xref>]. The easiest way for the formulation of buccal discs is direct compression [<xref rid="B134-pharmaceutics-17-00148" ref-type="bibr">134</xref>]. There are fewer buccal disc products on the market; some examples of them are OraMoist and XyliMelts.</p></sec><sec id="sec3dot4-pharmaceutics-17-00148"><title>3.4. Spray</title><p>Aerosol sprays are able to distribute the active ingredient evenly in the saliva or on the surface of the mucous membrane. Their use is convenient and simple for the patient, and the small droplets or particles can reduce the absorption time [<xref rid="B135-pharmaceutics-17-00148" ref-type="bibr">135</xref>]. This possibility plays a major role in researching the administration of protein- and peptide-type active substances as an alternative to injections. Buccal insulin spray, absorbed from the oral mucosa, produces a plasma concentration similar to subcutaneous insulin pens [<xref rid="B136-pharmaceutics-17-00148" ref-type="bibr">136</xref>], and its absorption can be improved with various excipients, like soy lecithin or propanediol [<xref rid="B137-pharmaceutics-17-00148" ref-type="bibr">137</xref>]. Currently, several buccal sprays are in development, based on the RapidMist technology, with various active ingredients, including vaccines. The aim of this formulation technology is to deliver liquid medicines into the mouth precisely and in exact quantities. The pharmacon is encapsulated in micelles of penetration enhancers and delivered in a high-velocity fine particle aerosol that spreads on the surface and traverses to the bloodstream through the mucosa, appearing in the circulation within 10 min after administration [<xref rid="B138-pharmaceutics-17-00148" ref-type="bibr">138</xref>]. Different types of buccal sprays are available, varying from local antibacterial preparations (Cepacol) to systemic nitroglycerin (Nitrolingual Pumpspray) and zolmitriptan (Zomig) medicines.</p></sec><sec id="sec3dot5-pharmaceutics-17-00148"><title>3.5. Films and Patches</title><p>The oral cavity mucous membrane is an excellent surface for modified drug release systems, as it is an extensive and immobile tissue. Mucoadhesive patches can be used to achieve a local or systemic effect. Release of the active ingredient is prolonged from them, and even with a lower active ingredient content, they provide a high plasma level curve and a stable pharmacon release (even hours later), compared to gels that wash off faster. Preparations on the market contain buprenorphine (Belbuca) and fentanyl (Onsolis), among others. There are ongoing experiments of immunization through buccal films to replace injections [<xref rid="B139-pharmaceutics-17-00148" ref-type="bibr">139</xref>].</p><p>These dosage forms are typically made by pouring a polymer solution, active ingredient, and excipients onto an appropriate surface and then drying it. Their size can vary widely, but a surface of 1&#x02013;3 cm<sup>2</sup> is ideal for application. In terms of pharmacon release, multidirectional and unidirectional preparations are distinguished; in the latter case, the polymer layer is applied to an impermeable background layer. Compared to buccal tablets, the films and patches are thinner and more flexible. This makes their use easier and more comfortable for the patient, but at the same time, the risks of damage, overhydration, and loss of adhesive properties of the product are also elevated [<xref rid="B140-pharmaceutics-17-00148" ref-type="bibr">140</xref>].</p><p>The solvent evaporation process is the primary method for production. The polymer is dissolved in a solvent or solvent mixture, and then the active ingredient is dissolved or dispersed in the liquid. It is then transferred to a suitable surface from which the solvent can evaporate, leaving behind a solid polymer film. Direct pressing and hot-melt extrusion are also popular production methods because of their avoidance of organic solvent use [<xref rid="B141-pharmaceutics-17-00148" ref-type="bibr">141</xref>,<xref rid="B142-pharmaceutics-17-00148" ref-type="bibr">142</xref>]. During hot-melt extrusion (HME), raw materials (active ingredients, polymers, excipients, etc.) are fed into the extrusion equipment, typically in a powder or granular form. Inside the extruder, the materials are subjected to controlled heat and shear force. This melts and homogenizes the mixture, creating a uniform mass. The molten mass is forced through a shaped die to produce the desired form. Then, the extruded material is cooled to solidify into its final form. Lastly, the extruded product is cut or shaped. Aside from the films, HME is a method for the production of pellets, granules, tablets, and solid dispersions and can achieve controlled release and taste masking [<xref rid="B143-pharmaceutics-17-00148" ref-type="bibr">143</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceutics-17-00148"><title>4. Conclusions</title><p>Looking at the scientific literature of recent years, it can be seen that oral mucosal drug delivery has serious potential. Its many advantages include convenient and simple use, versatility, modern technological options, and efficiency.</p><p>It can be seen that the trends are diverse within the field. The two main options for effective drug delivery are the longest possible retention time on the mucous membrane and, on the contrary, the fastest possible disintegration and active substance release. In the first case, the most important technological challenge is the selection of the right mucoadhesive polymer, which is biocompatible, leaves no residue or unpleasant feeling in the oral cavity, and provides a suitable controlled release of the active ingredient, which lasts sufficiently but not too long. The most frequently investigated mucoadhesive dosage forms are gels, films, and matrix tablets.</p><p>In the other case, the most difficult task is ensuring the relatively fast disintegration, often less than a minute, in a minimal amount of liquid. For this, a suitable disintegrant auxiliary material must be chosen, or an extremely porous structure must be created during the formulation process, all in balance, with sufficient stability before application. In this field, ODT tablets are the most popular, but their production requires careful planning and, in some cases, a more complicated technological process than is usual for oral tablets.</p><p>Both the longer retention time and rapid disintegration can be combined with technologies that increase the absorption of the active ingredient; in both cases, they lead to bioavailability enhancement.</p><p>Looking at the prevalence of oral mucosal drug delivery dosage forms, two trends can also be observed. The focus of scientific research is on more modern, complex drug delivery systems, such as nanoparticles or liposomes. In the case of products intended for commercial use, preference is given to formulations that can be developed and produced in a more cheap and simple way. Medicated jelly gums and lozenges can be considered a good example, as they are underrepresented in modern research compared to other forms of oral medicine, but at the same time, there is an increasing number of these types of preparations on the market.</p><p>Regardless of the pharmaceutical form, it is essential to create the right taste for all preparations used in the oral cavity. This can also be a challenge since the size of the carrier system limits the amount of excipients that can be used, while the typically bitter taste of the active ingredients requires a large amount of flavor enhancers. The subjectivity of taste perception also makes testing difficult. Determination of the appropriate taste effect in the planning phase is hard, even though the success of the commercial product and the therapy is decisively determined by this.</p><p>It is likely that these trends will converge in the future. As the effectiveness of the researched modern and complex pharmaceutical forms increases and their production becomes simpler, such preparations will be able to be marketed in a greater proportion. At the same time, the market can also have an impact on scientific research, and simpler, more commercially successful forms of medicine can also become more popular for researchers. The importance of oral drug delivery is indisputable, considering the number of scientific publications on the subject and patient compliance. An excellent example of the possibilities of the modern approach is that models of the oral mucosa have been developed to replace animal experiments, making research more ethical and taking sustainability into account [<xref rid="B144-pharmaceutics-17-00148" ref-type="bibr">144</xref>].</p><p>The increasing number of peptide-type pharmacons will probably make this route of administration even more important as an option to replace injections. Formulation solutions and methods of increasing bioavailability are currently diverse and are also the focus of research.</p><p>The future of oral mucosal drug delivery systems is likely to experience an increasing number of products made with different manufacturing technologies on the market, the expansion of ranges of active substances that can be used in this route due to various bioavailability enhancement methods, and the replacement of invasive intake in the case of biological therapy, vaccination, and peptide-type pharmacons.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00148"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lou</surname><given-names>J.</given-names></name>
<name><surname>Duan</surname><given-names>H.</given-names></name>
<name><surname>Qin</surname><given-names>Q.</given-names></name>
<name><surname>Teng</surname><given-names>Z.</given-names></name>
<name><surname>Gan</surname><given-names>F.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
</person-group><article-title>Advances in Oral Drug Delivery Systems: Challenges and Opportunities</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>484</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15020484</pub-id><pub-id pub-id-type="pmid">36839807</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00148"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alghanem</surname><given-names>S.</given-names></name>
<name><surname>Dziurkowska</surname><given-names>E.</given-names></name>
<name><surname>Ordyniec-Kwa&#x0015b;nica</surname><given-names>I.</given-names></name>
<name><surname>Sznitowska</surname><given-names>M.</given-names></name>
</person-group><article-title>Intraoral Medical Devices for Sustained Drug Delivery</article-title><source>Clin. Oral Investig.</source><year>2023</year><volume>27</volume><fpage>7157</fpage><lpage>7169</lpage><pub-id pub-id-type="doi">10.1007/s00784-023-05377-5</pub-id></element-citation></ref><ref id="B3-pharmaceutics-17-00148"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhati</surname><given-names>R.</given-names></name>
<name><surname>Nagrajan</surname><given-names>R.</given-names></name>
</person-group><article-title>A Detail Review on Oral Mucosa of Drug Delivery System</article-title><source>Int. J. Pharm. Sci. Res.</source><year>2012</year><volume>3</volume><fpage>659</fpage></element-citation></ref><ref id="B4-pharmaceutics-17-00148"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Madhav</surname><given-names>N.V.S.</given-names></name>
<name><surname>Shakya</surname><given-names>A.K.</given-names></name>
<name><surname>Shakya</surname><given-names>P.</given-names></name>
<name><surname>Singh</surname><given-names>K.</given-names></name>
</person-group><article-title>Orotransmucosal Drug Delivery Systems: A Review</article-title><source>J. Control Release</source><year>2009</year><volume>140</volume><fpage>2</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2009.07.016</pub-id><pub-id pub-id-type="pmid">19665039</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00148"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rathbone</surname><given-names>M.J.</given-names></name>
<name><surname>Tucker</surname><given-names>I.G.</given-names></name>
</person-group><article-title>Mechanisms, Barriers and Pathways of Oral Mucosal Drug Permeation</article-title><source>Adv. Drug Deliv. Rev.</source><year>1993</year><volume>12</volume><fpage>41</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/0169-409X(93)90040-B</pub-id></element-citation></ref><ref id="B6-pharmaceutics-17-00148"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Calpena Campmany</surname><given-names>A.C.</given-names></name>
<name><surname>Clares Naveros</surname><given-names>B.</given-names></name>
<name><surname>Fern&#x000e1;ndez</surname><given-names>F.</given-names></name>
</person-group><article-title>Technological, Biopharmaceutical and Pharmacokinetic Advances: New Formulations of Application on the Skin and Oral Mucosa</article-title><source>Recent Advances in Pharmaceutical Sciences</source><publisher-name>Transworld Research Network</publisher-name><publisher-loc>Trivandrum, India</publisher-loc><year>2011</year></element-citation></ref><ref id="B7-pharmaceutics-17-00148"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hooda</surname><given-names>R.</given-names></name>
<name><surname>Tripathi</surname><given-names>M.</given-names></name>
<name><surname>Kapoor</surname><given-names>P.K.</given-names></name>
</person-group><article-title>A Review on Oral Mucosal Drug Delivery System</article-title><source>Pharma Innov.</source><year>2012</year><volume>1</volume><fpage>14</fpage><lpage>21</lpage></element-citation></ref><ref id="B8-pharmaceutics-17-00148"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pather</surname><given-names>I.</given-names></name>
<name><surname>Rathbone</surname><given-names>M.</given-names></name>
<name><surname>Senel</surname><given-names>S.</given-names></name>
</person-group><article-title>Current Status and the Future of Buccal Drug Delivery Systems</article-title><source>Expert Opin. Drug Deliv.</source><year>2008</year><volume>5</volume><fpage>531</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1517/17425247.5.5.531</pub-id><pub-id pub-id-type="pmid">18491980</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00148"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ponchel</surname><given-names>G.</given-names></name>
</person-group><article-title>Formulation of Oral Mucosal Drug Delivery Systems for the Systemic Delivery of Bioactive Materials</article-title><source>Adv. Drug Deliv. Rev.</source><year>1994</year><volume>13</volume><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/0169-409X(94)90027-2</pub-id></element-citation></ref><ref id="B10-pharmaceutics-17-00148"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Segale</surname><given-names>L.</given-names></name>
<name><surname>Maggi</surname><given-names>L.</given-names></name>
<name><surname>Machiste</surname><given-names>E.</given-names></name>
<name><surname>Conti</surname><given-names>S.</given-names></name>
<name><surname>Conte</surname><given-names>U.</given-names></name>
<name><surname>Grenier</surname><given-names>A.</given-names></name>
<name><surname>Besse</surname><given-names>C.</given-names></name>
</person-group><article-title>Formulation Design and Development to Produce Orodispersible Tablets by Direct Compression</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2007</year><volume>17</volume><fpage>199</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/S1773-2247(07)50036-5</pub-id></element-citation></ref><ref id="B11-pharmaceutics-17-00148"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silvers</surname><given-names>A.R.</given-names></name>
<name><surname>Som</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Salivary Glands</article-title><source>Radiol. Clin. N. Am.</source><year>1998</year><volume>36</volume><fpage>941</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1016/S0033-8389(05)70070-1</pub-id><pub-id pub-id-type="pmid">9747195</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00148"><label>12.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Witt</surname><given-names>M.</given-names></name>
</person-group><article-title>Chapter 10&#x02014;Anatomy and Development of the Human Taste System</article-title><source>Handbook of Clinical Neurology</source><comment>Smel and Taste</comment><person-group person-group-type="editor">
<name><surname>Doty</surname><given-names>R.L.</given-names></name>
</person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2019</year><volume>Volume 164</volume><fpage>147</fpage><lpage>171</lpage></element-citation></ref><ref id="B13-pharmaceutics-17-00148"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.-S.</given-names></name>
<name><surname>Tang</surname><given-names>Y.-L.</given-names></name>
<name><surname>Pang</surname><given-names>X.</given-names></name>
<name><surname>Zheng</surname><given-names>M.</given-names></name>
<name><surname>Tang</surname><given-names>Y.-J.</given-names></name>
<name><surname>Liang</surname><given-names>X.-H.</given-names></name>
</person-group><article-title>The Maintenance of an Oral Epithelial Barrier</article-title><source>Life Sci.</source><year>2019</year><volume>227</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2019.04.029</pub-id><pub-id pub-id-type="pmid">31002922</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00148"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kido</surname><given-names>M.A.</given-names></name>
<name><surname>Yoshimoto</surname><given-names>R.U.</given-names></name>
<name><surname>Aijima</surname><given-names>R.</given-names></name>
<name><surname>Cao</surname><given-names>A.-L.</given-names></name>
<name><surname>Gao</surname><given-names>W.-Q.</given-names></name>
</person-group><article-title>The Oral Mucosal Membrane and Transient Receptor Potential Channels</article-title><source>J. Oral Sci.</source><year>2017</year><volume>59</volume><fpage>189</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.2334/josnusd.16-0862</pub-id><pub-id pub-id-type="pmid">28637977</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00148"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Domenech</surname><given-names>E.</given-names></name>
<name><surname>Kelly</surname><given-names>J.</given-names></name>
</person-group><article-title>Swallowing disorders</article-title><source>Med. Clin. N. Am.</source><year>1999</year><volume>83</volume><fpage>97</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/S0025-7125(05)70090-0</pub-id><pub-id pub-id-type="pmid">9927963</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00148"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ketel</surname><given-names>E.C.</given-names></name>
<name><surname>de Wijk</surname><given-names>R.A.</given-names></name>
<name><surname>de Graaf</surname><given-names>C.</given-names></name>
<name><surname>Stieger</surname><given-names>M.</given-names></name>
</person-group><article-title>Relating Oral Physiology and Anatomy of Consumers Varying in Age, Gender and Ethnicity to Food Oral Processing Behavior</article-title><source>Physiol. Behav.</source><year>2020</year><volume>215</volume><fpage>112766</fpage><pub-id pub-id-type="doi">10.1016/j.physbeh.2019.112766</pub-id><pub-id pub-id-type="pmid">31812520</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00148"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sasegbon</surname><given-names>A.</given-names></name>
<name><surname>Hamdy</surname><given-names>S.</given-names></name>
</person-group><article-title>The Anatomy and Physiology of Normal and Abnormal Swallowing in Oropharyngeal Dysphagia</article-title><source>Neurogastroenterol. Motil.</source><year>2017</year><volume>29</volume><fpage>e13100</fpage><pub-id pub-id-type="doi">10.1111/nmo.13100</pub-id><pub-id pub-id-type="pmid">28547793</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00148"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laffleur</surname><given-names>F.</given-names></name>
<name><surname>Bernkop-Schn&#x000fc;rch</surname><given-names>A.</given-names></name>
</person-group><article-title>Strategies for Improving Mucosal Drug Delivery</article-title><source>Nanomedicine</source><year>2013</year><volume>8</volume><fpage>2061</fpage><lpage>2075</lpage><pub-id pub-id-type="doi">10.2217/nnm.13.178</pub-id><pub-id pub-id-type="pmid">24279493</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00148"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Streisand</surname><given-names>J.B.</given-names></name>
</person-group><article-title>Oral Mucosal Drug Delivery: Clinical Pharmacokinetics and Therapeutic Applications</article-title><source>Clin. Pharmacokinet.</source><year>2002</year><volume>41</volume><fpage>661</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.2165/00003088-200241090-00003</pub-id><pub-id pub-id-type="pmid">12126458</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00148"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hannan</surname><given-names>P.A.</given-names></name>
<name><surname>Khan</surname><given-names>J.A.</given-names></name>
<name><surname>Khan</surname><given-names>A.</given-names></name>
<name><surname>Safiullah</surname><given-names>S.</given-names></name>
</person-group><article-title>Oral Dispersible System: A New Approach in Drug Delivery System</article-title><source>Indian J. Pharm. Sci.</source><year>2016</year><volume>78</volume><fpage>2</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4103/0250-474X.180244</pub-id><pub-id pub-id-type="pmid">27168675</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00148"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elshafeey</surname><given-names>A.H.</given-names></name>
<name><surname>El-Dahmy</surname><given-names>R.M.</given-names></name>
</person-group><article-title>A Novel Oral Medicated Jelly for Enhancement of Etilefrine Hydrochloride Bioavailability: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers</article-title><source>Saudi Pharm. J. SPJ Off. Publ. Saudi Pharm. Soc.</source><year>2022</year><volume>30</volume><fpage>1435</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2022.07.004</pub-id></element-citation></ref><ref id="B22-pharmaceutics-17-00148"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farias</surname><given-names>S.</given-names></name>
<name><surname>Boateng</surname><given-names>J.S.</given-names></name>
</person-group><article-title>In Vitro, Ex Vivo and in Vivo Evaluation of Taste Masked Low Dose Acetylsalicylic Acid Loaded Composite Wafers as Platforms for Buccal Administration in Geriatric Patients with Dysphagia</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>589</volume><fpage>119807</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119807</pub-id><pub-id pub-id-type="pmid">32882368</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00148"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fating</surname><given-names>H.</given-names></name>
<name><surname>Ambadkar</surname><given-names>J.</given-names></name>
<name><surname>Kajale</surname><given-names>A.</given-names></name>
</person-group><article-title>Advances in Taste Masking of Drug: A Review Study</article-title><source>J. Drug Deliv. Ther.</source><year>2022</year><volume>12</volume><fpage>255</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.22270/jddt.v12i3-S.5442</pub-id></element-citation></ref><ref id="B24-pharmaceutics-17-00148"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nasr</surname><given-names>N.E.H.</given-names></name>
<name><surname>ElMeshad</surname><given-names>A.N.</given-names></name>
<name><surname>Fares</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Nanocarrier Systems in Taste Masking</article-title><source>Sci. Pharm.</source><year>2022</year><volume>90</volume><elocation-id>20</elocation-id><pub-id pub-id-type="doi">10.3390/scipharm90010020</pub-id></element-citation></ref><ref id="B25-pharmaceutics-17-00148"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rana</surname><given-names>S.S.</given-names></name>
<name><surname>Kharbanda</surname><given-names>O.P.</given-names></name>
<name><surname>Agarwal</surname><given-names>B.</given-names></name>
</person-group><article-title>Influence of Tongue Volume, Oral Cavity Volume and Their Ratio on Upper Airway: A Cone Beam Computed Tomography Study</article-title><source>J. Oral Biol. Craniofac. Res.</source><year>2020</year><volume>10</volume><fpage>110</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.jobcr.2020.03.006</pub-id><pub-id pub-id-type="pmid">32215247</pub-id>
</element-citation></ref><ref id="B26-pharmaceutics-17-00148"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chore</surname><given-names>S.A.</given-names></name>
<name><surname>Dighade</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Review on Buccal Drug Delivery System</article-title><source>Int. J. Pharm. Sci. Rev. Res.</source><year>2020</year><volume>65</volume><fpage>140</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.47583/ijpsrr.2020.v65i02.022</pub-id></element-citation></ref><ref id="B27-pharmaceutics-17-00148"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hao</surname><given-names>J.</given-names></name>
<name><surname>Heng</surname><given-names>P.W.S.</given-names></name>
</person-group><article-title>Buccal Delivery Systems</article-title><source>Drug Dev. Ind. Pharm.</source><year>2003</year><volume>29</volume><fpage>821</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1081/DDC-120024178</pub-id><pub-id pub-id-type="pmid">14570303</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-17-00148"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roblegg</surname><given-names>E.</given-names></name>
<name><surname>Coughran</surname><given-names>A.</given-names></name>
<name><surname>Sirjani</surname><given-names>D.</given-names></name>
</person-group><article-title>Saliva: An All-Rounder of Our Body</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2019</year><volume>142</volume><fpage>133</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2019.06.016</pub-id><pub-id pub-id-type="pmid">31220573</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00148"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>V.F.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Brown</surname><given-names>M.B.</given-names></name>
</person-group><article-title>Advances in Oral Transmucosal Drug Delivery</article-title><source>J. Control. Release</source><year>2011</year><volume>153</volume><fpage>106</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2011.01.027</pub-id><pub-id pub-id-type="pmid">21300115</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00148"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Serpe</surname><given-names>L.</given-names></name>
<name><surname>Jain</surname><given-names>A.</given-names></name>
<name><surname>de Macedo</surname><given-names>C.G.</given-names></name>
<name><surname>Volpato</surname><given-names>M.C.</given-names></name>
<name><surname>Groppo</surname><given-names>F.C.</given-names></name>
<name><surname>Gill</surname><given-names>H.S.</given-names></name>
<name><surname>Franz-Montan</surname><given-names>M.</given-names></name>
</person-group><article-title>Influence of Salivary Washout on Drug Delivery to the Oral Cavity Using Coated Microneedles: An in Vitro Evaluation</article-title><source>Eur. J. Pharm. Sci.</source><year>2016</year><volume>93</volume><fpage>215</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2016.08.023</pub-id><pub-id pub-id-type="pmid">27523787</pub-id>
</element-citation></ref><ref id="B31-pharmaceutics-17-00148"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>M.</given-names></name>
<name><surname>Bai</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Ying</surname><given-names>B.</given-names></name>
</person-group><article-title>Promising Applications of Human-Derived Saliva Biomarker Testing in Clinical Diagnostics</article-title><source>Int. J. Oral Sci.</source><year>2023</year><volume>15</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/s41368-022-00209-w</pub-id><pub-id pub-id-type="pmid">36593250</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00148"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hua</surname><given-names>S.</given-names></name>
</person-group><article-title>Physiological and Pharmaceutical Considerations for Rectal Drug Formulations</article-title><source>Front. Pharmacol.</source><year>2019</year><volume>10</volume><elocation-id>1196</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2019.01196</pub-id><pub-id pub-id-type="pmid">31680970</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00148"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mudie</surname><given-names>D.M.</given-names></name>
<name><surname>Amidon</surname><given-names>G.L.</given-names></name>
<name><surname>Amidon</surname><given-names>G.E.</given-names></name>
</person-group><article-title>Physiological Parameters for Oral Delivery and In Vitro Testing</article-title><source>Mol. Pharm.</source><year>2010</year><volume>7</volume><fpage>1388</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1021/mp100149j</pub-id><pub-id pub-id-type="pmid">20822152</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-17-00148"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schiller</surname><given-names>C.</given-names></name>
<name><surname>Fr&#x000f6;hlich</surname><given-names>C.-P.</given-names></name>
<name><surname>Giessmann</surname><given-names>T.</given-names></name>
<name><surname>Siegmund</surname><given-names>W.</given-names></name>
<name><surname>M&#x000f6;nnikes</surname><given-names>H.</given-names></name>
<name><surname>Hosten</surname><given-names>N.</given-names></name>
<name><surname>Weitschies</surname><given-names>W.</given-names></name>
</person-group><article-title>Intestinal Fluid Volumes and Transit of Dosage Forms as Assessed by Magnetic Resonance Imaging</article-title><source>Aliment. Pharmacol. Ther.</source><year>2005</year><volume>22</volume><fpage>971</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2005.02683.x</pub-id><pub-id pub-id-type="pmid">16268972</pub-id>
</element-citation></ref><ref id="B35-pharmaceutics-17-00148"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leal</surname><given-names>J.</given-names></name>
<name><surname>Smyth</surname><given-names>H.D.C.</given-names></name>
<name><surname>Ghosh</surname><given-names>D.</given-names></name>
</person-group><article-title>Physicochemical Properties of Mucus and Their Impact on Transmucosal Drug Delivery</article-title><source>Int. J. Pharm.</source><year>2017</year><volume>532</volume><fpage>555</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.09.018</pub-id><pub-id pub-id-type="pmid">28917986</pub-id>
</element-citation></ref><ref id="B36-pharmaceutics-17-00148"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Golshani</surname><given-names>S.</given-names></name>
<name><surname>Vatanara</surname><given-names>A.</given-names></name>
<name><surname>Amin</surname><given-names>M.</given-names></name>
</person-group><article-title>Recent Advances in Oral Mucoadhesive Drug Delivery</article-title><source>J. Pharm. Pharm. Sci.</source><year>2022</year><volume>25</volume><fpage>201</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.18433/jpps32705</pub-id><pub-id pub-id-type="pmid">35714375</pub-id>
</element-citation></ref><ref id="B37-pharmaceutics-17-00148"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lesch</surname><given-names>C.A.</given-names></name>
<name><surname>Squier</surname><given-names>C.A.</given-names></name>
<name><surname>Cruchley</surname><given-names>A.</given-names></name>
<name><surname>Williams</surname><given-names>D.M.</given-names></name>
<name><surname>Speight</surname><given-names>P.</given-names></name>
</person-group><article-title>The Permeability of Human Oral Mucosa and Skin to Water</article-title><source>J. Dent. Res.</source><year>1989</year><volume>68</volume><fpage>1345</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1177/00220345890680091101</pub-id><pub-id pub-id-type="pmid">2476469</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00148"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matoltsy</surname><given-names>A.G.</given-names></name>
<name><surname>Parakkal</surname><given-names>P.F.</given-names></name>
</person-group><article-title>Membrane-coating granules of keratinizing epithelia</article-title><source>J. Cell Biol.</source><year>1965</year><volume>24</volume><fpage>297</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1083/jcb.24.2.297</pub-id><pub-id pub-id-type="pmid">14326115</pub-id>
</element-citation></ref><ref id="B39-pharmaceutics-17-00148"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bierbaumer</surname><given-names>L.</given-names></name>
<name><surname>Schwarze</surname><given-names>U.Y.</given-names></name>
<name><surname>Gruber</surname><given-names>R.</given-names></name>
<name><surname>Neuhaus</surname><given-names>W.</given-names></name>
</person-group><article-title>Cell Culture Models of Oral Mucosal Barriers: A Review with a Focus on Applications, Culture Conditions and Barrier Properties</article-title><source>Tissue Barriers</source><year>2018</year><volume>6</volume><fpage>1479568</fpage><pub-id pub-id-type="doi">10.1080/21688370.2018.1479568</pub-id><pub-id pub-id-type="pmid">30252599</pub-id>
</element-citation></ref><ref id="B40-pharmaceutics-17-00148"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sayed</surname><given-names>O.M.</given-names></name>
</person-group><article-title>Oral Mucosal Absorption: Mechanisms, Methods, and Challenges in Drug Delivery</article-title><source>Int. J. Clin. Med. Res.</source><year>2024</year><volume>2</volume><fpage>155</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.61466/ijcmr2050002</pub-id><pub-id pub-id-type="pmid">9098874</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00148"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Utoguchi</surname><given-names>N.</given-names></name>
<name><surname>Watanabe</surname><given-names>Y.</given-names></name>
<name><surname>Suzuki</surname><given-names>T.</given-names></name>
<name><surname>Maehara</surname><given-names>J.</given-names></name>
<name><surname>Matsumoto</surname><given-names>Y.</given-names></name>
<name><surname>Matsumoto</surname><given-names>M.</given-names></name>
</person-group><article-title>Carrier-Mediated Transport of Monocarboxylic Acids in Primary Cultured Epithelial Cells from Rabbit Oral Mucosa</article-title><source>Pharm. Res.</source><year>1997</year><volume>14</volume><fpage>320</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1023/A:1012046021028</pub-id><pub-id pub-id-type="pmid">9098874</pub-id>
</element-citation></ref><ref id="B42-pharmaceutics-17-00148"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oyama</surname><given-names>Y.</given-names></name>
<name><surname>Yamano</surname><given-names>H.</given-names></name>
<name><surname>Ohkuma</surname><given-names>A.</given-names></name>
<name><surname>Ogawara</surname><given-names>K.</given-names></name>
<name><surname>Higaki</surname><given-names>K.</given-names></name>
<name><surname>Kimura</surname><given-names>T.</given-names></name>
</person-group><article-title>Carrier-Mediated Transport Systems for Glucose in Mucosal Cells of the Human Oral Cavity</article-title><source>J. Pharm. Sci.</source><year>1999</year><volume>88</volume><fpage>830</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1021/js980298f</pub-id><pub-id pub-id-type="pmid">10430550</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00148"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Streekstra</surname><given-names>E.J.</given-names></name>
<name><surname>Keuper-Navis</surname><given-names>M.</given-names></name>
<name><surname>van den Heuvel</surname><given-names>J.J.</given-names></name>
<name><surname>van den Broek</surname><given-names>P.</given-names></name>
<name><surname>Stommel</surname><given-names>M.W.</given-names></name>
<name><surname>Bervoets</surname><given-names>S.</given-names></name>
<name><surname>O&#x02019;Gorman</surname><given-names>L.</given-names></name>
<name><surname>Greupink</surname><given-names>R.</given-names></name>
<name><surname>Russel</surname><given-names>F.G.</given-names></name>
<name><surname>van de Steeg</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Human Enteroid Monolayers as a Potential Alternative for Ussing Chamber and Caco-2 Monolayers to Study Passive Permeability and Drug Efflux</article-title><source>Eur. J. Pharm. Sci.</source><year>2024</year><volume>201</volume><fpage>106877</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2024.106877</pub-id><pub-id pub-id-type="pmid">39154715</pub-id>
</element-citation></ref><ref id="B44-pharmaceutics-17-00148"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maeda</surname><given-names>K.</given-names></name>
</person-group><article-title>New Method of Measurement of Epidermal Turnover in Humans</article-title><source>Cosmetics</source><year>2017</year><volume>4</volume><elocation-id>47</elocation-id><pub-id pub-id-type="doi">10.3390/cosmetics4040047</pub-id></element-citation></ref><ref id="B45-pharmaceutics-17-00148"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Naik</surname><given-names>P.K.</given-names></name>
<name><surname>Pradhan</surname><given-names>D.</given-names></name>
<name><surname>Ghosh</surname><given-names>G.</given-names></name>
<name><surname>Rath</surname><given-names>G.</given-names></name>
</person-group><article-title>Mucoadhesive Formulations: Innovations, Merits, Drawbacks, and Future Outlook</article-title><source>Pharm. Dev. Technol.</source><year>2020</year><volume>25</volume><fpage>797</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1080/10837450.2020.1753771</pub-id><pub-id pub-id-type="pmid">32267180</pub-id>
</element-citation></ref><ref id="B46-pharmaceutics-17-00148"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shaikh</surname><given-names>R.</given-names></name>
<name><surname>Raj Singh</surname><given-names>T.R.</given-names></name>
<name><surname>Garland</surname><given-names>M.J.</given-names></name>
<name><surname>Woolfson</surname><given-names>A.D.</given-names></name>
<name><surname>Donnelly</surname><given-names>R.F.</given-names></name>
</person-group><article-title>Mucoadhesive Drug Delivery Systems</article-title><source>J. Pharm. Bioallied Sci.</source><year>2011</year><volume>3</volume><fpage>89</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.4103/0975-7406.76478</pub-id><pub-id pub-id-type="pmid">21430958</pub-id>
</element-citation></ref><ref id="B47-pharmaceutics-17-00148"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yapto</surname><given-names>C.V.</given-names></name>
<name><surname>Rajes</surname><given-names>K.</given-names></name>
<name><surname>Inselmann</surname><given-names>A.</given-names></name>
<name><surname>Staufenbiel</surname><given-names>S.</given-names></name>
<name><surname>Stolte</surname><given-names>K.N.</given-names></name>
<name><surname>Witt</surname><given-names>M.</given-names></name>
<name><surname>Haag</surname><given-names>R.</given-names></name>
<name><surname>Dommisch</surname><given-names>H.</given-names></name>
<name><surname>Danker</surname><given-names>K.</given-names></name>
</person-group><article-title>Topical Application of Dexamethasone-Loaded Core-Multishell Nanocarriers Against Oral Mucosal Inflammation</article-title><source>Macromol. Biosci.</source><year>2024</year><volume>24</volume><elocation-id>2400286</elocation-id><pub-id pub-id-type="doi">10.1002/mabi.202400286</pub-id><pub-id pub-id-type="pmid">39363619</pub-id>
</element-citation></ref><ref id="B48-pharmaceutics-17-00148"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Roesger</surname><given-names>S.</given-names></name>
<name><surname>Jones</surname><given-names>N.</given-names></name>
<name><surname>Hu</surname><given-names>C.-M.J.</given-names></name>
<name><surname>Li</surname><given-names>S.-D.</given-names></name>
</person-group><article-title>Cell-Penetrating Peptides for Transmucosal Delivery of Proteins</article-title><source>J. Control. Release</source><year>2024</year><volume>366</volume><fpage>864</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.01.038</pub-id><pub-id pub-id-type="pmid">38272399</pub-id>
</element-citation></ref><ref id="B49-pharmaceutics-17-00148"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>W.</given-names></name>
<name><surname>Xue</surname><given-names>S.</given-names></name>
<name><surname>Sheng</surname><given-names>Y.</given-names></name>
<name><surname>Gao</surname><given-names>B.</given-names></name>
<name><surname>Dang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
</person-group><article-title>&#x003b2;-Cyclodextrin/Dialdehyde Glucan-Coated Keratin Nanoparticles for Oral Delivery of Insulin</article-title><source>Int. J. Biol. Macromol.</source><year>2024</year><volume>276</volume><elocation-id>133805</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.133805</pub-id><pub-id pub-id-type="pmid">38996885</pub-id>
</element-citation></ref><ref id="B50-pharmaceutics-17-00148"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hassan</surname><given-names>A.</given-names></name>
<name><surname>Khan</surname><given-names>J.A.</given-names></name>
<name><surname>Nasir</surname><given-names>F.</given-names></name>
<name><surname>Shabir</surname><given-names>H.</given-names></name>
<name><surname>Hannan</surname><given-names>P.A.</given-names></name>
<name><surname>Ullah</surname><given-names>R.</given-names></name>
<name><surname>Jan</surname><given-names>A.</given-names></name>
<name><surname>Khalid</surname><given-names>A.</given-names></name>
<name><surname>Khan</surname><given-names>A.</given-names></name>
<name><surname>Al-Harrasi</surname><given-names>A.</given-names></name>
</person-group><article-title>Synthesis, Characterization, and Stability Optimization of Ibuprofen Cocrystals eEploying Various Hydrophilic Polymers</article-title><source>Curr. Pharm. Des.</source><year>2024</year><volume>31</volume><fpage>873</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.2174/0113816128305926240530051853</pub-id><pub-id pub-id-type="pmid">38867533</pub-id>
</element-citation></ref><ref id="B51-pharmaceutics-17-00148"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nandhini</surname><given-names>J.</given-names></name>
<name><surname>Anandhi</surname><given-names>B.</given-names></name>
<name><surname>Patnaik</surname><given-names>S.S.</given-names></name>
<name><surname>Shirole</surname><given-names>R.L.</given-names></name>
<name><surname>Mourya</surname><given-names>N.D.</given-names></name>
<name><surname>Siddiqui</surname><given-names>N.</given-names></name>
<name><surname>Mathew</surname><given-names>J.</given-names></name>
<name><surname>Ravikkumar</surname><given-names>V.R.</given-names></name>
<name><surname>Karthikeyan</surname><given-names>E.</given-names></name>
</person-group><article-title>Design and Development of Propranolol HCl Fast Dissolving Tablets by Using Isolated Mucilage of Salvia Hispanica for the Treatment of Hypertension by Using DoE Tools</article-title><source>Zhongguo Ying Yong Sheng Li Xue Za Zhi</source><year>2024</year><volume>40</volume><fpage>e20240025</fpage><pub-id pub-id-type="doi">10.62958/j.cjap.2024.025</pub-id><pub-id pub-id-type="pmid">39210543</pub-id>
</element-citation></ref><ref id="B52-pharmaceutics-17-00148"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Svirskis</surname><given-names>D.</given-names></name>
<name><surname>Proft</surname><given-names>T.</given-names></name>
<name><surname>Loh</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Kang</surname><given-names>D.</given-names></name>
<name><surname>Wen</surname><given-names>J.</given-names></name>
</person-group><article-title>Exploring Ex Vivo Peptideolysis of Thymopentin and Lipid-Based Nanocarriers towards Oral Formulations</article-title><source>Int. J. Pharm.</source><year>2022</year><volume>625</volume><fpage>122123</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.122123</pub-id><pub-id pub-id-type="pmid">35995317</pub-id>
</element-citation></ref><ref id="B53-pharmaceutics-17-00148"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shah</surname><given-names>R.B.</given-names></name>
<name><surname>Palamakula</surname><given-names>A.</given-names></name>
<name><surname>Khan</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Cytotoxicity Evaluation of Enzyme Inhibitors and Absorption Enhancers in Caco-2 Cells for Oral Delivery of Salmon Calcitonin</article-title><source>J. Pharm. Sci.</source><year>2004</year><volume>93</volume><fpage>1070</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1002/jps.20007</pub-id><pub-id pub-id-type="pmid">14999743</pub-id>
</element-citation></ref><ref id="B54-pharmaceutics-17-00148"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boateng</surname><given-names>J.S.</given-names></name>
<name><surname>Mitchell</surname><given-names>J.C.</given-names></name>
<name><surname>Pawar</surname><given-names>H.</given-names></name>
<name><surname>Ayensu</surname><given-names>I.</given-names></name>
</person-group><article-title>Functional Characterisation and Permeation Studies of Lyophilised Thiolated Chitosan Xerogels for Buccal Delivery of Insulin</article-title><source>Protein Pept. Lett.</source><year>2014</year><volume>21</volume><fpage>1163</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.2174/0929866521666140805124403</pub-id><pub-id pub-id-type="pmid">25101633</pub-id>
</element-citation></ref><ref id="B55-pharmaceutics-17-00148"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Christrup</surname><given-names>L.L.</given-names></name>
<name><surname>J&#x000f8;rgensen</surname><given-names>A.</given-names></name>
<name><surname>Christensen</surname><given-names>C.B.</given-names></name>
<name><surname>Friis</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Improvement of Buccal Delivery of Morphine Using the Prodrug Approach</article-title><source>Int. J. Pharm.</source><year>1997</year><volume>154</volume><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(97)00128-2</pub-id></element-citation></ref><ref id="B56-pharmaceutics-17-00148"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kroth</surname><given-names>R.</given-names></name>
<name><surname>Cristiano Monteiro</surname><given-names>M.</given-names></name>
<name><surname>Conte</surname><given-names>J.</given-names></name>
<name><surname>Fretes Argenta</surname><given-names>D.</given-names></name>
<name><surname>Amaral</surname><given-names>B.R.</given-names></name>
<name><surname>Szpoganicz</surname><given-names>B.</given-names></name>
<name><surname>Caon</surname><given-names>T.</given-names></name>
</person-group><article-title>Transbuccal Delivery of Metal Complexes of Isoniazid as an Alternative to Overcome Antimicrobial Resistance Problems</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>590</volume><fpage>119924</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119924</pub-id><pub-id pub-id-type="pmid">33053418</pub-id>
</element-citation></ref><ref id="B57-pharmaceutics-17-00148"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scaturro</surname><given-names>A.L.</given-names></name>
<name><surname>De Caro</surname><given-names>V.</given-names></name>
<name><surname>Campisi</surname><given-names>G.</given-names></name>
<name><surname>Giannola</surname><given-names>L.I.</given-names></name>
</person-group><article-title>Potential Transbuccal Delivery of L-DOPA Methylester Prodrug: Stability in the Environment of the Oral Cavity and Ability to Cross the Mucosal Tissue</article-title><source>Drug Deliv.</source><year>2016</year><volume>23</volume><fpage>2355</fpage><lpage>2362</lpage><pub-id pub-id-type="doi">10.3109/10717544.2014.987332</pub-id><pub-id pub-id-type="pmid">25533875</pub-id>
</element-citation></ref><ref id="B58-pharmaceutics-17-00148"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>G&#x000fc;ltekin</surname><given-names>H.E.</given-names></name>
<name><surname>Ayd&#x00131;n</surname><given-names>H.H.</given-names></name>
<name><surname>&#x0015e;ahiner</surname><given-names>A.</given-names></name>
<name><surname>Soylu</surname><given-names>F.E.</given-names></name>
<name><surname>&#x0015e;enyi&#x0011f;it</surname><given-names>Z.</given-names></name>
<name><surname>Karay&#x00131;ld&#x00131;r&#x00131;m</surname><given-names>&#x000c7;.K.</given-names></name>
</person-group><article-title>In Vitro and in Vivo Evaluation of Tedizolid Nanoparticle Incorporated Buccal Films for Oromucosal Infections</article-title><source>Int. J. Pharm.</source><year>2024</year><volume>665</volume><fpage>124688</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2024.124688</pub-id><pub-id pub-id-type="pmid">39293576</pub-id>
</element-citation></ref><ref id="B59-pharmaceutics-17-00148"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghadhban</surname><given-names>H.Y.</given-names></name>
<name><surname>Ahmed</surname><given-names>K.K.</given-names></name>
</person-group><article-title>Nanosuspension-Based Repaglinide Fast-Dissolving Buccal Film for Dissolution Enhancement</article-title><source>AAPS PharmSciTech</source><year>2024</year><volume>25</volume><fpage>161</fpage><pub-id pub-id-type="doi">10.1208/s12249-024-02868-w</pub-id><pub-id pub-id-type="pmid">38992175</pub-id>
</element-citation></ref><ref id="B60-pharmaceutics-17-00148"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>W.</given-names></name>
<name><surname>Ngo</surname><given-names>H.V.</given-names></name>
<name><surname>Nguyen</surname><given-names>H.D.</given-names></name>
<name><surname>Park</surname><given-names>J.-M.</given-names></name>
<name><surname>Lee</surname><given-names>K.W.</given-names></name>
<name><surname>Park</surname><given-names>C.</given-names></name>
<name><surname>Park</surname><given-names>J.-B.</given-names></name>
<name><surname>Lee</surname><given-names>B.-J.</given-names></name>
</person-group><article-title>Nanonization and Deformable Behavior of Fattigated Peptide Drug in Mucoadhesive Buccal Films</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>468</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16040468</pub-id><pub-id pub-id-type="pmid">38675128</pub-id>
</element-citation></ref><ref id="B61-pharmaceutics-17-00148"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haghighatseir</surname><given-names>N.</given-names></name>
<name><surname>Mozafari</surname><given-names>N.</given-names></name>
<name><surname>Shadvand</surname><given-names>E.</given-names></name>
<name><surname>Ashrafi</surname><given-names>H.</given-names></name>
<name><surname>Daneshamouz</surname><given-names>S.</given-names></name>
<name><surname>Azadi</surname><given-names>A.</given-names></name>
</person-group><article-title>Mixed-Micelle in Situ Gel as a Candidate for Oral Inflammatory Ulcerative Diseases</article-title><source>AAPS PharmSciTech</source><year>2024</year><volume>25</volume><fpage>144</fpage><pub-id pub-id-type="doi">10.1208/s12249-024-02862-2</pub-id><pub-id pub-id-type="pmid">38918282</pub-id>
</element-citation></ref><ref id="B62-pharmaceutics-17-00148"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ameta</surname><given-names>R.K.</given-names></name>
<name><surname>Soni</surname><given-names>K.</given-names></name>
<name><surname>Bhattarai</surname><given-names>A.</given-names></name>
</person-group><article-title>Recent Advances in Improving the Bioavailability of Hydrophobic/Lipophilic Drugs and Their Delivery via Self-Emulsifying Formulations</article-title><source>Colloids Interfaces</source><year>2023</year><volume>7</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.3390/colloids7010016</pub-id></element-citation></ref><ref id="B63-pharmaceutics-17-00148"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Porter</surname><given-names>C.J.H.</given-names></name>
<name><surname>Trevaskis</surname><given-names>N.L.</given-names></name>
<name><surname>Charman</surname><given-names>W.N.</given-names></name>
</person-group><article-title>Lipids and Lipid-Based Formulations: Optimizing the Oral Delivery of Lipophilic Drugs</article-title><source>Nat. Rev. Drug Discov.</source><year>2007</year><volume>6</volume><fpage>231</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/nrd2197</pub-id><pub-id pub-id-type="pmid">17330072</pub-id>
</element-citation></ref><ref id="B64-pharmaceutics-17-00148"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sandmeier</surname><given-names>M.</given-names></name>
<name><surname>Hoeng</surname><given-names>J.</given-names></name>
<name><surname>Skov Jensen</surname><given-names>S.</given-names></name>
<name><surname>Nykj&#x000e6;r Nikolajsen</surname><given-names>G.</given-names></name>
<name><surname>Ziegler Bruun</surname><given-names>H.</given-names></name>
<name><surname>To</surname><given-names>D.</given-names></name>
<name><surname>Ricci</surname><given-names>F.</given-names></name>
<name><surname>Schifferle</surname><given-names>M.</given-names></name>
<name><surname>Bernkop-Schn&#x000fc;rch</surname><given-names>A.</given-names></name>
</person-group><article-title>Oral Formulations for Highly Lipophilic Drugs: Impact of Surface Decoration on the Efficacy of Self-Emulsifying Drug Delivery Systems</article-title><source>J. Colloid Interface Sci.</source><year>2025</year><volume>677</volume><fpage>1108</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1016/j.jcis.2024.07.233</pub-id><pub-id pub-id-type="pmid">39142152</pub-id>
</element-citation></ref><ref id="B65-pharmaceutics-17-00148"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Jes&#x000fa;s Valle</surname><given-names>M.J.</given-names></name>
<name><surname>Rondon Mujica</surname><given-names>A.M.</given-names></name>
<name><surname>Zarzuelo Casta&#x000f1;eda</surname><given-names>A.</given-names></name>
<name><surname>Coutinho</surname><given-names>P.</given-names></name>
<name><surname>de Abreu Duarte</surname><given-names>A.C.</given-names></name>
<name><surname>S&#x000e1;nchez Navarro</surname><given-names>A.</given-names></name>
</person-group><article-title>Resveratrol Liposomes in Buccal Formulations, an Approach to Overcome Drawbacks Limiting the Application of the Phytoactive Molecule for Chemoprevention and Treatment of Oral Cancer</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2024</year><volume>98</volume><fpage>105910</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2024.105910</pub-id></element-citation></ref><ref id="B66-pharmaceutics-17-00148"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Jes&#x000fa;s Valle</surname><given-names>M.J.</given-names></name>
<name><surname>Zarzuelo Casta&#x000f1;eda</surname><given-names>A.</given-names></name>
<name><surname>Maderuelo</surname><given-names>C.</given-names></name>
<name><surname>Cencerrado Trevi&#x000f1;o</surname><given-names>A.</given-names></name>
<name><surname>Loureiro</surname><given-names>J.</given-names></name>
<name><surname>Coutinho</surname><given-names>P.</given-names></name>
<name><surname>S&#x000e1;nchez Navarro</surname><given-names>A.</given-names></name>
</person-group><article-title>Development of a Mucoadhesive Vehicle Based on Lyophilized Liposomes for Drug Delivery through the Sublingual Mucosa</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>1497</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14071497</pub-id><pub-id pub-id-type="pmid">35890395</pub-id>
</element-citation></ref><ref id="B67-pharmaceutics-17-00148"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keum</surname><given-names>T.</given-names></name>
<name><surname>Noh</surname><given-names>G.</given-names></name>
<name><surname>Seo</surname><given-names>J.-E.</given-names></name>
<name><surname>Bashyal</surname><given-names>S.</given-names></name>
<name><surname>Sohn</surname><given-names>D.H.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
</person-group><article-title>Examination of Effective Buccal Absorption of Salmon Calcitonin Using Cell-Penetrating Peptide-Conjugated Liposomal Drug Delivery System</article-title><source>Int. J. Nanomed.</source><year>2022</year><volume>17</volume><fpage>697</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.2147/IJN.S335774</pub-id></element-citation></ref><ref id="B68-pharmaceutics-17-00148"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Okafor</surname><given-names>N.I.</given-names></name>
<name><surname>Ngoepe</surname><given-names>M.</given-names></name>
<name><surname>Noundou</surname><given-names>X.S.</given-names></name>
<name><surname>Ma&#x000e7;edo Krause</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Nano-Enabled Liposomal Mucoadhesive Films for Enhanced Efavirenz Buccal Drug Delivery</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2019</year><volume>54</volume><fpage>101312</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2019.101312</pub-id></element-citation></ref><ref id="B69-pharmaceutics-17-00148"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smart</surname><given-names>J.D.</given-names></name>
</person-group><article-title>The Basics and Underlying Mechanisms of Mucoadhesion</article-title><source>Adv. Drug Deliv. Rev.</source><year>2005</year><volume>57</volume><fpage>1556</fpage><lpage>1568</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2005.07.001</pub-id><pub-id pub-id-type="pmid">16198441</pub-id>
</element-citation></ref><ref id="B70-pharmaceutics-17-00148"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jim&#x000e9;nez-castellanos</surname><given-names>M.R.</given-names></name>
<name><surname>Zia</surname><given-names>H.</given-names></name>
<name><surname>Rhodes</surname><given-names>C.T.</given-names></name>
</person-group><article-title>Mucoadhesive Drug Delivery Systems</article-title><source>Drug Dev. Ind. Pharm.</source><year>1993</year><volume>19</volume><fpage>143</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.3109/03639049309038765</pub-id></element-citation></ref><ref id="B71-pharmaceutics-17-00148"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boddupalli</surname><given-names>B.M.</given-names></name>
<name><surname>Mohammed</surname><given-names>Z.N.K.</given-names></name>
<name><surname>Nath</surname><given-names>R.A.</given-names></name>
<name><surname>Banji</surname><given-names>D.</given-names></name>
</person-group><article-title>Mucoadhesive Drug Delivery System: An Overview</article-title><source>J. Adv. Pharm. Technol. Res.</source><year>2010</year><volume>1</volume><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.4103/0110-5558.76436</pub-id><pub-id pub-id-type="pmid">22247877</pub-id>
</element-citation></ref><ref id="B72-pharmaceutics-17-00148"><label>72.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Yaqoob</surname><given-names>M.</given-names></name>
<name><surname>Jalil</surname><given-names>A.</given-names></name>
<name><surname>Bernkop-Schn&#x000fc;rch</surname><given-names>A.</given-names></name>
</person-group><article-title>Chapter 20&#x02014;Mucoadhesive Polymers: Gateway to Innovative Drug Delivery</article-title><source>Modeling and Control of Drug Delivery Systems</source><person-group person-group-type="editor">
<name><surname>Azar</surname><given-names>A.T.</given-names></name>
</person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2021</year><fpage>351</fpage><lpage>383</lpage><isbn>978-0-12-821185-4</isbn></element-citation></ref><ref id="B73-pharmaceutics-17-00148"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Komati</surname><given-names>S.</given-names></name>
<name><surname>Swain</surname><given-names>S.</given-names></name>
<name><surname>Rao</surname><given-names>M.E.B.</given-names></name>
<name><surname>Jena</surname><given-names>B.R.</given-names></name>
<name><surname>Dasi</surname><given-names>V.</given-names></name>
</person-group><article-title>Mucoadhesive Multiparticulate Drug Delivery Systems: An Extensive Review of Patents</article-title><source>Adv. Pharm. Bull.</source><year>2019</year><volume>9</volume><fpage>521</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.15171/apb.2019.062</pub-id><pub-id pub-id-type="pmid">31857957</pub-id>
</element-citation></ref><ref id="B74-pharmaceutics-17-00148"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vakili</surname><given-names>M.R.</given-names></name>
<name><surname>Mohammed-Saeid</surname><given-names>W.</given-names></name>
<name><surname>Aljasser</surname><given-names>A.</given-names></name>
<name><surname>Hopwood-Raja</surname><given-names>J.</given-names></name>
<name><surname>Ahvazi</surname><given-names>B.</given-names></name>
<name><surname>Hrynets</surname><given-names>Y.</given-names></name>
<name><surname>Betti</surname><given-names>M.</given-names></name>
<name><surname>Lavasanifar</surname><given-names>A.</given-names></name>
</person-group><article-title>Development of Mucoadhesive Hydrogels Based on Polyacrylic Acid Grafted Cellulose Nanocrystals for Local Cisplatin Delivery</article-title><source>Carbohydr. Polym.</source><year>2021</year><volume>255</volume><fpage>117332</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2020.117332</pub-id><pub-id pub-id-type="pmid">33436175</pub-id>
</element-citation></ref><ref id="B75-pharmaceutics-17-00148"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cook</surname><given-names>S.L.</given-names></name>
<name><surname>Woods</surname><given-names>S.</given-names></name>
<name><surname>Methven</surname><given-names>L.</given-names></name>
<name><surname>Parker</surname><given-names>J.K.</given-names></name>
<name><surname>Khutoryanskiy</surname><given-names>V.V.</given-names></name>
</person-group><article-title>Mucoadhesive Polysaccharides Modulate Sodium Retention, Release and Taste Perception</article-title><source>Food Chem.</source><year>2018</year><volume>240</volume><fpage>482</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2017.07.134</pub-id><pub-id pub-id-type="pmid">28946301</pub-id>
</element-citation></ref><ref id="B76-pharmaceutics-17-00148"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ways</surname><given-names>T.M.M.</given-names></name>
<name><surname>Lau</surname><given-names>W.M.</given-names></name>
<name><surname>Khutoryanskiy</surname><given-names>V.V.</given-names></name>
</person-group><article-title>Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems</article-title><source>Polymers</source><year>2018</year><volume>10</volume><elocation-id>267</elocation-id><pub-id pub-id-type="doi">10.3390/polym10030267</pub-id><pub-id pub-id-type="pmid">30966302</pub-id>
</element-citation></ref><ref id="B77-pharmaceutics-17-00148"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szyma&#x00144;ska</surname><given-names>E.</given-names></name>
<name><surname>Winnicka</surname><given-names>K.</given-names></name>
</person-group><article-title>Stability of Chitosan&#x02014;A Challenge for Pharmaceutical and Biomedical Applications</article-title><source>Mar. Drugs</source><year>2015</year><volume>13</volume><fpage>1819</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.3390/md13041819</pub-id><pub-id pub-id-type="pmid">25837983</pub-id>
</element-citation></ref><ref id="B78-pharmaceutics-17-00148"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lehr</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Lectin-Mediated Drug Delivery: The Second Generation of Bioadhesives</article-title><source>J. Control. Release</source><year>2000</year><volume>65</volume><fpage>19</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/S0168-3659(99)00228-X</pub-id><pub-id pub-id-type="pmid">10699266</pub-id>
</element-citation></ref><ref id="B79-pharmaceutics-17-00148"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mfoafo</surname><given-names>K.</given-names></name>
<name><surname>Mittal</surname><given-names>R.</given-names></name>
<name><surname>Eshraghi</surname><given-names>A.</given-names></name>
<name><surname>Omidi</surname><given-names>Y.</given-names></name>
<name><surname>Omidian</surname><given-names>H.</given-names></name>
</person-group><article-title>Thiolated Polymers: An Overview of Mucoadhesive Properties and Their Potential in Drug Delivery via Mucosal Tissues</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2023</year><volume>85</volume><fpage>104596</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2023.104596</pub-id></element-citation></ref><ref id="B80-pharmaceutics-17-00148"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sep&#x000fa;lveda-C&#x000f3;rdova</surname><given-names>A.</given-names></name>
<name><surname>Fern&#x000e1;ndez-Mart&#x000ed;nez</surname><given-names>T.</given-names></name>
<name><surname>Campos-Requena</surname><given-names>V.H.</given-names></name>
</person-group><article-title>Synthesis of Thiomer/Nanoclay Nanocomposites as a Potential Drug Carrier: Evaluation of Mucoadhesive and Controlled Release Properties</article-title><source>J. Pharm. Sci</source><year>2024</year><volume>113</volume><fpage>3323</fpage><lpage>3331</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2024.08.030</pub-id><pub-id pub-id-type="pmid">39216537</pub-id>
</element-citation></ref><ref id="B81-pharmaceutics-17-00148"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meher</surname><given-names>J.</given-names></name>
<name><surname>Yadav</surname><given-names>N.</given-names></name>
<name><surname>Yadav</surname><given-names>K.</given-names></name>
<name><surname>Rai</surname><given-names>V.</given-names></name>
</person-group><article-title>Buccal Drug Delivery System and Penetration Enhancer: A Review</article-title><source>Pharma Rev.</source><year>2012</year><volume>10</volume><fpage>113</fpage><lpage>117</lpage></element-citation></ref><ref id="B82-pharmaceutics-17-00148"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tawfeek</surname><given-names>H.M.</given-names></name>
<name><surname>Hassan</surname><given-names>Y.A.</given-names></name>
<name><surname>Aldawsari</surname><given-names>M.F.</given-names></name>
<name><surname>Fayed</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization</article-title><source>Pharmaceuticals</source><year>2020</year><volume>13</volume><elocation-id>446</elocation-id><pub-id pub-id-type="doi">10.3390/ph13120446</pub-id><pub-id pub-id-type="pmid">33291402</pub-id>
</element-citation></ref><ref id="B83-pharmaceutics-17-00148"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haddadzadegan</surname><given-names>S.</given-names></name>
<name><surname>Dorkoosh</surname><given-names>F.</given-names></name>
<name><surname>Bernkop-Schn&#x000fc;rch</surname><given-names>A.</given-names></name>
</person-group><article-title>Oral Delivery of Therapeutic Peptides and Proteins: Technology Landscape of Lipid-Based Nanocarriers</article-title><source>Adv. Drug Deliv. Rev.</source><year>2022</year><volume>182</volume><fpage>114097</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.114097</pub-id><pub-id pub-id-type="pmid">34999121</pub-id>
</element-citation></ref><ref id="B84-pharmaceutics-17-00148"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jacob</surname><given-names>S.</given-names></name>
<name><surname>Nair</surname><given-names>A.B.</given-names></name>
<name><surname>Boddu</surname><given-names>S.H.S.</given-names></name>
<name><surname>Gorain</surname><given-names>B.</given-names></name>
<name><surname>Sreeharsha</surname><given-names>N.</given-names></name>
<name><surname>Shah</surname><given-names>J.</given-names></name>
</person-group><article-title>An Updated Overview of the Emerging Role of Patch and Film-Based Buccal Delivery Systems</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>1206</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13081206</pub-id><pub-id pub-id-type="pmid">34452167</pub-id>
</element-citation></ref><ref id="B85-pharmaceutics-17-00148"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>Q.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Paul</surname><given-names>P.K.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Qi</surname><given-names>J.</given-names></name>
</person-group><article-title>Oral Delivery of Proteins and Peptides: Challenges, Status Quo and Future Perspectives</article-title><source>Acta Pharm. Sin. B</source><year>2021</year><volume>11</volume><fpage>2416</fpage><lpage>2448</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2021.04.001</pub-id><pub-id pub-id-type="pmid">34522593</pub-id>
</element-citation></ref><ref id="B86-pharmaceutics-17-00148"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dahan</surname><given-names>A.</given-names></name>
<name><surname>Zimmermann</surname><given-names>E.M.</given-names></name>
<name><surname>Ben-Shabat</surname><given-names>S.</given-names></name>
</person-group><article-title>Modern Prodrug Design for Targeted Oral Drug Delivery</article-title><source>Molecules</source><year>2014</year><volume>19</volume><fpage>16489</fpage><lpage>16505</lpage><pub-id pub-id-type="doi">10.3390/molecules191016489</pub-id><pub-id pub-id-type="pmid">25317578</pub-id>
</element-citation></ref><ref id="B87-pharmaceutics-17-00148"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mok</surname><given-names>Z.H.</given-names></name>
</person-group><article-title>The Effect of Particle Size on Drug Bioavailability in Various Parts of the Body</article-title><source>Pharm. Sci. Adv.</source><year>2024</year><volume>2</volume><fpage>100031</fpage><pub-id pub-id-type="doi">10.1016/j.pscia.2023.100031</pub-id></element-citation></ref><ref id="B88-pharmaceutics-17-00148"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rao</surname><given-names>S.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Peddie</surname><given-names>F.</given-names></name>
<name><surname>Evans</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Particle Size Reduction to the Nanometer Range: A Promising Approach to Improve Buccal Absorption of Poorly Water-Soluble Drugs</article-title><source>Int. J. Nanomed.</source><year>2011</year><volume>6</volume><fpage>1245</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.2147/IJN.S19151</pub-id></element-citation></ref><ref id="B89-pharmaceutics-17-00148"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kokate</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Jasti</surname><given-names>B.</given-names></name>
</person-group><article-title>Effect of Drug Lipophilicity and Ionization on Permeability Across the Buccal Mucosa: A Technical Note</article-title><source>AAPS PharmSciTech</source><year>2008</year><volume>9</volume><fpage>501</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1208/s12249-008-9071-7</pub-id><pub-id pub-id-type="pmid">18431653</pub-id>
</element-citation></ref><ref id="B90-pharmaceutics-17-00148"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>H.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Qi</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>Q.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
</person-group><article-title>Adapting Liposomes for Oral Drug Delivery</article-title><source>Acta Pharm. Sin. B</source><year>2019</year><volume>9</volume><fpage>36</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2018.06.005</pub-id><pub-id pub-id-type="pmid">30766776</pub-id>
</element-citation></ref><ref id="B91-pharmaceutics-17-00148"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Gong</surname><given-names>X.</given-names></name>
<name><surname>Cai</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>H.-Y.</given-names></name>
<name><surname>Forbes</surname><given-names>B.</given-names></name>
</person-group><article-title>Pullulan-Based Spray-Dried Mucoadhesive Microparticles for Sustained Oromucosal Drug Delivery</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>460</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16040460</pub-id><pub-id pub-id-type="pmid">38675121</pub-id>
</element-citation></ref><ref id="B92-pharmaceutics-17-00148"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sakurai</surname><given-names>H.</given-names></name>
<name><surname>Ikeuchi-Takahashi</surname><given-names>Y.</given-names></name>
<name><surname>Kobayashi</surname><given-names>A.</given-names></name>
<name><surname>Yoshimura</surname><given-names>N.</given-names></name>
<name><surname>Ishihara</surname><given-names>C.</given-names></name>
<name><surname>Aomori</surname><given-names>T.</given-names></name>
<name><surname>Onishi</surname><given-names>H.</given-names></name>
</person-group><article-title>Formulation Development of Mucoadhesive Microparticle-Laden Gels for Oral Mucositis: An In Vitro and In Vivo Study</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>603</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12070603</pub-id><pub-id pub-id-type="pmid">32610442</pub-id>
</element-citation></ref><ref id="B93-pharmaceutics-17-00148"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oh</surname><given-names>M.J.</given-names></name>
<name><surname>Kim</surname><given-names>J.-H.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Xiang</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Koo</surname><given-names>H.</given-names></name>
<name><surname>Lee</surname><given-names>D.</given-names></name>
</person-group><article-title>Drug-Loaded Adhesive Microparticles for Biofilm Prevention on Oral Surfaces</article-title><source>J. Mater. Chem. B</source><year>2024</year><volume>12</volume><fpage>4935</fpage><lpage>4944</lpage><pub-id pub-id-type="doi">10.1039/D4TB00134F</pub-id><pub-id pub-id-type="pmid">38683039</pub-id>
</element-citation></ref><ref id="B94-pharmaceutics-17-00148"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tzanova</surname><given-names>M.M.</given-names></name>
<name><surname>Hagesaether</surname><given-names>E.</given-names></name>
<name><surname>Tho</surname><given-names>I.</given-names></name>
</person-group><article-title>Solid Lipid Nanoparticle-Loaded Mucoadhesive Buccal Films&#x02014;Critical Quality Attributes and in Vitro Safety &#x00026; Efficacy</article-title><source>Int. J. Pharm.</source><year>2021</year><volume>592</volume><fpage>120100</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.120100</pub-id><pub-id pub-id-type="pmid">33227374</pub-id>
</element-citation></ref><ref id="B95-pharmaceutics-17-00148"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Teubl</surname><given-names>B.J.</given-names></name>
<name><surname>Meindl</surname><given-names>C.</given-names></name>
<name><surname>Eitzlmayr</surname><given-names>A.</given-names></name>
<name><surname>Zimmer</surname><given-names>A.</given-names></name>
<name><surname>Fr&#x000f6;hlich</surname><given-names>E.</given-names></name>
<name><surname>Roblegg</surname><given-names>E.</given-names></name>
</person-group><article-title>In-Vitro Permeability of Neutral Polystyrene Particles via Buccal Mucosa</article-title><source>Small</source><year>2013</year><volume>9</volume><fpage>457</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1002/smll.201201789</pub-id><pub-id pub-id-type="pmid">23112142</pub-id>
</element-citation></ref><ref id="B96-pharmaceutics-17-00148"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gatto</surname><given-names>M.S.</given-names></name>
<name><surname>Najahi-Missaoui</surname><given-names>W.</given-names></name>
</person-group><article-title>Lyophilization of Nanoparticles, Does It Really Work? Overview of the Current Status and Challenges</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>14041</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241814041</pub-id><pub-id pub-id-type="pmid">37762348</pub-id>
</element-citation></ref><ref id="B97-pharmaceutics-17-00148"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gadade</surname><given-names>D.D.</given-names></name>
<name><surname>Pekamwar</surname><given-names>S.S.</given-names></name>
</person-group><article-title>Cyclodextrin Based Nanoparticles for Drug Delivery and Theranostics</article-title><source>Adv. Pharm. Bull.</source><year>2020</year><volume>10</volume><fpage>166</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.34172/apb.2020.022</pub-id><pub-id pub-id-type="pmid">32373486</pub-id>
</element-citation></ref><ref id="B98-pharmaceutics-17-00148"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McGrath</surname><given-names>C.</given-names></name>
<name><surname>Clarkson</surname><given-names>J.</given-names></name>
<name><surname>Glenny</surname><given-names>A.-M.</given-names></name>
<name><surname>Walsh</surname><given-names>L.J.</given-names></name>
<name><surname>Hua</surname><given-names>F.</given-names></name>
</person-group><article-title>Effectiveness of Mouthwashes in Managing Oral Diseases and Conditions: Do They Have a Role?</article-title><source>Int. Dent. J.</source><year>2023</year><volume>73</volume><fpage>S69</fpage><lpage>S73</lpage><pub-id pub-id-type="doi">10.1016/j.identj.2023.08.014</pub-id><pub-id pub-id-type="pmid">37867064</pub-id>
</element-citation></ref><ref id="B99-pharmaceutics-17-00148"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brookes</surname><given-names>Z.L.</given-names></name>
<name><surname>McCullough</surname><given-names>M.</given-names></name>
<name><surname>Kumar</surname><given-names>P.</given-names></name>
<name><surname>McGrath</surname><given-names>C.</given-names></name>
</person-group><article-title>Mouthwashes: Implications for Practice</article-title><source>Int. Dent. J.</source><year>2023</year><volume>73</volume><issue>(Suppl. S2)</issue><fpage>S98</fpage><lpage>S101</lpage><pub-id pub-id-type="doi">10.1016/j.identj.2023.08.013</pub-id><pub-id pub-id-type="pmid">37867062</pub-id>
</element-citation></ref><ref id="B100-pharmaceutics-17-00148"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torne</surname><given-names>S.R.</given-names></name>
<name><surname>Sheela</surname><given-names>A.</given-names></name>
<name><surname>Sarada</surname><given-names>N.C.</given-names></name>
</person-group><article-title>A Review on Oral Liquid as an Emerging Technology in Controlled Drug Delivery System</article-title><source>Curr. Pharm. Des.</source><year>2018</year><volume>24</volume><fpage>1349</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.2174/1381612824666171204102800</pub-id><pub-id pub-id-type="pmid">29205111</pub-id>
</element-citation></ref><ref id="B101-pharmaceutics-17-00148"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wanasathop</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Iontophoretic Drug Delivery in the Oral Cavity</article-title><source>Pharmaceutics</source><year>2018</year><volume>10</volume><elocation-id>121</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics10030121</pub-id><pub-id pub-id-type="pmid">30087247</pub-id>
</element-citation></ref><ref id="B102-pharmaceutics-17-00148"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Caro</surname><given-names>V.</given-names></name>
<name><surname>Giannola</surname><given-names>L.I.</given-names></name>
<name><surname>Di Prima</surname><given-names>G.</given-names></name>
</person-group><article-title>Solid and Semisolid Innovative Formulations Containing Miconazole-Loaded Solid Lipid Microparticles to Promote Drug Entrapment into the Buccal Mucosa</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>1361</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13091361</pub-id><pub-id pub-id-type="pmid">34575437</pub-id>
</element-citation></ref><ref id="B103-pharmaceutics-17-00148"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dubashynskaya</surname><given-names>N.V.</given-names></name>
<name><surname>Petrova</surname><given-names>V.A.</given-names></name>
<name><surname>Skorik</surname><given-names>Y.A.</given-names></name>
</person-group><article-title>Biopolymer Drug Delivery Systems for Oromucosal Application: Recent Trends in Pharmaceutical R&#x00026;D</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>5359</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25105359</pub-id><pub-id pub-id-type="pmid">38791397</pub-id>
</element-citation></ref><ref id="B104-pharmaceutics-17-00148"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chanda</surname><given-names>R.</given-names></name>
<name><surname>Nallaguntla</surname><given-names>L.</given-names></name>
</person-group><article-title>Formulation and evaluation of medicated lozenges for sore throat</article-title><source>Asian J. Pharm. Clin. Res.</source><year>2020</year><volume>13</volume><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.22159/ajpcr.2020.v13i10.38660</pub-id></element-citation></ref><ref id="B105-pharmaceutics-17-00148"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alissa</surname><given-names>M.</given-names></name>
<name><surname>Hjazi</surname><given-names>A.</given-names></name>
<name><surname>Abusalim</surname><given-names>G.S.</given-names></name>
<name><surname>Aloraini</surname><given-names>G.S.</given-names></name>
<name><surname>Alghamdi</surname><given-names>S.A.</given-names></name>
<name><surname>Rizg</surname><given-names>W.Y.</given-names></name>
<name><surname>Hosny</surname><given-names>K.M.</given-names></name>
<name><surname>Alblowi</surname><given-names>J.A.</given-names></name>
<name><surname>Alkharobi</surname><given-names>H.</given-names></name>
</person-group><article-title>Development and Optimization of a Novel Lozenge Containing a Metronidazole-Peppermint Oil-Tranexamic Acid Self-Nanoemulsified Delivery System to Be Used after Dental Extraction: In Vitro Evaluation and In Vivo Appraisal</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>2342</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15092342</pub-id><pub-id pub-id-type="pmid">37765310</pub-id>
</element-citation></ref><ref id="B106-pharmaceutics-17-00148"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blanchard</surname><given-names>O.L.</given-names></name>
<name><surname>Friesenhahn</surname><given-names>G.</given-names></name>
<name><surname>Javors</surname><given-names>M.A.</given-names></name>
<name><surname>Smoliga</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Development of a Lozenge for Oral Transmucosal Delivery of Trans-Resveratrol in Humans: Proof of Concept</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e90131</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0090131</pub-id><pub-id pub-id-type="pmid">24587240</pub-id>
</element-citation></ref><ref id="B107-pharmaceutics-17-00148"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kulkarni</surname><given-names>M.P.</given-names></name>
<name><surname>Sharma</surname><given-names>A.</given-names></name>
<name><surname>Tanwar</surname><given-names>S.</given-names></name>
<name><surname>Vandana</surname><given-names>P.B.</given-names></name>
<name><surname>Wadhwa</surname><given-names>S.</given-names></name>
<name><surname>Singh</surname><given-names>G.</given-names></name>
<name><surname>Kumar</surname><given-names>P.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
</person-group><article-title>Pharmaceutical Lozenges: Recent Trends and Developments with an Update on Research and Patents</article-title><source>Recent Adv. Drug Deliv. Formul.</source><year>2022</year><volume>16</volume><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.2174/2667387816666211231103759</pub-id><pub-id pub-id-type="pmid">34970962</pub-id>
</element-citation></ref><ref id="B108-pharmaceutics-17-00148"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pothu</surname><given-names>R.</given-names></name>
<name><surname>Yamsani</surname><given-names>M.</given-names></name>
</person-group><article-title>Lozenges formulation and evaluation: A review</article-title><source>Int. J. Pharm. Sci. Rev. Res.</source><year>2014</year><volume>5</volume><fpage>290</fpage><lpage>298</lpage></element-citation></ref><ref id="B109-pharmaceutics-17-00148"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aslani</surname><given-names>A.</given-names></name>
<name><surname>Rostami</surname><given-names>F.</given-names></name>
</person-group><article-title>Medicated Chewing Gum, a Novel Drug Delivery System</article-title><source>J. Res. Med. Sci.</source><year>2015</year><volume>20</volume><fpage>403</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">26109999</pub-id>
</element-citation></ref><ref id="B110-pharmaceutics-17-00148"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaushik</surname><given-names>P.</given-names></name>
<name><surname>Mittal</surname><given-names>V.</given-names></name>
<name><surname>Kaushik</surname><given-names>D.</given-names></name>
</person-group><article-title>Unleashing the Potential of &#x003b2; -Cyclodextrin Inclusion Complexes in Bitter Taste Abatement: Development, Optimization and Evaluation of Taste Masked Anti-Emetic Chewing Gum of Promethazine Hydrochloride</article-title><source>AAPS PharmSciTech</source><year>2024</year><volume>25</volume><fpage>169</fpage><pub-id pub-id-type="doi">10.1208/s12249-024-02888-6</pub-id><pub-id pub-id-type="pmid">39043992</pub-id>
</element-citation></ref><ref id="B111-pharmaceutics-17-00148"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bruschi</surname><given-names>M.L.</given-names></name>
<name><surname>de Freitas</surname><given-names>O.</given-names></name>
</person-group><article-title>Oral Bioadhesive Drug Delivery Systems</article-title><source>Drug Dev. Ind. Pharm.</source><year>2005</year><volume>31</volume><fpage>293</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1081/DDC-52073</pub-id><pub-id pub-id-type="pmid">15830725</pub-id>
</element-citation></ref><ref id="B112-pharmaceutics-17-00148"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>S.</given-names></name>
<name><surname>Sandri</surname><given-names>G.</given-names></name>
<name><surname>Caramella</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Buccal Drug Delivery: A Challenge Already Won?</article-title><source>Drug Discov. Today Technol.</source><year>2005</year><volume>2</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.ddtec.2005.05.018</pub-id><pub-id pub-id-type="pmid">24981756</pub-id>
</element-citation></ref><ref id="B113-pharmaceutics-17-00148"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koirala</surname><given-names>S.</given-names></name>
<name><surname>Nepal</surname><given-names>P.</given-names></name>
<name><surname>Ghimire</surname><given-names>G.</given-names></name>
<name><surname>Basnet</surname><given-names>R.</given-names></name>
<name><surname>Rawat</surname><given-names>I.</given-names></name>
<name><surname>Dahal</surname><given-names>A.</given-names></name>
<name><surname>Pandey</surname><given-names>J.</given-names></name>
<name><surname>Parajuli-Baral</surname><given-names>K.</given-names></name>
</person-group><article-title>Formulation and Evaluation of Mucoadhesive Buccal Tablets of Aceclofenac</article-title><source>Heliyon</source><year>2021</year><volume>7</volume><fpage>e06439</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2021.e06439</pub-id><pub-id pub-id-type="pmid">33786387</pub-id>
</element-citation></ref><ref id="B114-pharmaceutics-17-00148"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>S.</given-names></name>
<name><surname>Chaurasia</surname><given-names>A.</given-names></name>
<name><surname>Gupta</surname><given-names>N.</given-names></name>
<name><surname>Rajput</surname><given-names>D.S.</given-names></name>
</person-group><article-title>Effect of Formulation Parameters on Enalapril Maleate Mucoadhesive Buccal Tablet Using Quality by Design (QbD) Approach</article-title><source>Zhongguo Ying Yong Sheng Li Xue Za Zhi</source><year>2024</year><volume>40</volume><fpage>e20240003</fpage><pub-id pub-id-type="doi">10.62958/j.cjap.2024.003</pub-id><pub-id pub-id-type="pmid">38925868</pub-id>
</element-citation></ref><ref id="B115-pharmaceutics-17-00148"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Woyna-Orlewicz</surname><given-names>K.</given-names></name>
<name><surname>Brniak</surname><given-names>W.</given-names></name>
<name><surname>Tatara</surname><given-names>W.</given-names></name>
<name><surname>Strzebo&#x00144;ska</surname><given-names>M.</given-names></name>
<name><surname>Haznar-Garbacz</surname><given-names>D.</given-names></name>
<name><surname>Szafraniec-Szcz&#x00119;sny</surname><given-names>J.</given-names></name>
<name><surname>Antosik-Rog&#x000f3;&#x0017c;</surname><given-names>A.</given-names></name>
<name><surname>Wojteczko</surname><given-names>K.</given-names></name>
<name><surname>Str&#x000f3;zik</surname><given-names>M.</given-names></name>
<name><surname>Kurek</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Investigating the Impact of Co-Processed Excipients on the Formulation of Bromhexine Hydrochloride Orally Disintegrating Tablets (ODTs)</article-title><source>Pharm. Res.</source><year>2023</year><volume>40</volume><fpage>2947</fpage><lpage>2962</lpage><pub-id pub-id-type="doi">10.1007/s11095-023-03605-x</pub-id><pub-id pub-id-type="pmid">37726407</pub-id>
</element-citation></ref><ref id="B116-pharmaceutics-17-00148"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bandari</surname><given-names>S.</given-names></name>
<name><surname>Mittapalli</surname><given-names>R.</given-names></name>
<name><surname>Gannu</surname><given-names>R.</given-names></name>
<name><surname>Yamsani</surname><given-names>M.</given-names></name>
</person-group><article-title>Orodispersible Tablets: An Overview</article-title><source>Asian J. Pharm.</source><year>2008</year><volume>2</volume><fpage>2</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.4103/0973-8398.41557</pub-id></element-citation></ref><ref id="B117-pharmaceutics-17-00148"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dey</surname><given-names>P.</given-names></name>
<name><surname>Maiti</surname><given-names>S.</given-names></name>
</person-group><article-title>Orodispersible Tablets: A New Trend in Drug Delivery</article-title><source>J. Nat. Sci. Biol. Med.</source><year>2010</year><volume>1</volume><fpage>2</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.4103/0976-9668.71663</pub-id><pub-id pub-id-type="pmid">22096326</pub-id>
</element-citation></ref><ref id="B118-pharmaceutics-17-00148"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pawar</surname><given-names>H.</given-names></name>
<name><surname>Varkhade</surname><given-names>C.</given-names></name>
<name><surname>Jadhav</surname><given-names>P.</given-names></name>
<name><surname>Mehra</surname><given-names>K.</given-names></name>
</person-group><article-title>Development and Evaluation of Orodispersible Tablets Using a Natural Polysaccharide Isolated from Cassia Tora Seeds</article-title><source>Integr. Med. Res.</source><year>2014</year><volume>3</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.imr.2014.03.002</pub-id><pub-id pub-id-type="pmid">28664083</pub-id>
</element-citation></ref><ref id="B119-pharmaceutics-17-00148"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elkhodairy</surname><given-names>K.A.</given-names></name>
<name><surname>Hassan</surname><given-names>M.A.</given-names></name>
<name><surname>Afifi</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Formulation and Optimization of Orodispersible Tablets of Flutamide</article-title><source>Saudi Pharm. J.</source><year>2014</year><volume>22</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2013.01.009</pub-id><pub-id pub-id-type="pmid">24493974</pub-id>
</element-citation></ref><ref id="B120-pharmaceutics-17-00148"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Panda</surname><given-names>S.</given-names></name>
<name><surname>Hemalatha</surname><given-names>N.</given-names></name>
<name><surname>Shankar</surname><given-names>P.U.</given-names></name>
<name><surname>Baratam</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Formulation and evaluation of orodispersible tablets (odts) of diclofenac sodium by using superdisintegrant from natural origin</article-title><source>Int. J. Appl. Pharm.</source><year>2019</year><volume>11</volume><fpage>190</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.22159/ijap.2019v11i6.33480</pub-id></element-citation></ref><ref id="B121-pharmaceutics-17-00148"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jeevanandham</surname><given-names>S.</given-names></name>
<name><surname>Dhachinamoorthi</surname><given-names>D.</given-names></name>
<name><surname>Sekhar</surname><given-names>K.C.</given-names></name>
<name><surname>Muthukumaran</surname><given-names>M.</given-names></name>
<name><surname>Sriram</surname><given-names>N.</given-names></name>
<name><surname>Joysaruby</surname><given-names>J.</given-names></name>
</person-group><article-title>Formulation and Evaluation of Naproxen Sodium Orodispersible Tablets&#x02014;A Sublimation Technique</article-title><source>Asian J. Pharm.</source><year>2010</year><volume>4</volume><fpage>48</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.4103/0973-8398.63985</pub-id></element-citation></ref><ref id="B122-pharmaceutics-17-00148"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kalyankar</surname><given-names>P.</given-names></name>
<name><surname>Panzade</surname><given-names>P.</given-names></name>
<name><surname>Lahoti</surname><given-names>S.</given-names></name>
</person-group><article-title>Formulation Design and Optimization of Orodispersible Tablets of Quetiapine Fumarate by Sublimation Method</article-title><source>Indian J. Pharm. Sci.</source><year>2015</year><volume>77</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.4103/0250-474x.159605</pub-id><pub-id pub-id-type="pmid">26180271</pub-id>
</element-citation></ref><ref id="B123-pharmaceutics-17-00148"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tran</surname><given-names>P.H.L.</given-names></name>
<name><surname>Lee</surname><given-names>B.-J.</given-names></name>
<name><surname>Tran</surname><given-names>T.T.D.</given-names></name>
</person-group><article-title>Strategies and Formulations of Freeze-Dried Tablets for Controlled Drug Delivery</article-title><source>Int. J. Pharm.</source><year>2021</year><volume>597</volume><fpage>120373</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120373</pub-id><pub-id pub-id-type="pmid">33577912</pub-id>
</element-citation></ref><ref id="B124-pharmaceutics-17-00148"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vanbillemont</surname><given-names>B.</given-names></name>
<name><surname>Everaert</surname><given-names>H.</given-names></name>
<name><surname>De Beer</surname><given-names>T.</given-names></name>
</person-group><article-title>New Advances in the Characterization of Lyophilised Orally Disintegrating Tablets</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>579</volume><fpage>119153</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119153</pub-id><pub-id pub-id-type="pmid">32084575</pub-id>
</element-citation></ref><ref id="B125-pharmaceutics-17-00148"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Authelin</surname><given-names>J.R.</given-names></name>
<name><surname>Koumurian</surname><given-names>B.</given-names></name>
<name><surname>Meagher</surname><given-names>K.</given-names></name>
<name><surname>Walsh</surname><given-names>E.</given-names></name>
<name><surname>Clavreul</surname><given-names>T.</given-names></name>
<name><surname>Rellis</surname><given-names>B.</given-names></name>
<name><surname>Gerbeau</surname><given-names>L.</given-names></name>
<name><surname>Nakach</surname><given-names>M.</given-names></name>
<name><surname>Peral</surname><given-names>F.</given-names></name>
</person-group><article-title>A Simple and Cost-Effective Technique to Monitor the Sublimation Flow During Primary Drying of Freeze-Drying Using Shelf Inlet/Outlet Temperature Difference or Chamber to Condenser Pressure Drop</article-title><source>J. Pharm. Sci.</source><year>2024</year><volume>113</volume><fpage>1898</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2024.02.015</pub-id><pub-id pub-id-type="pmid">38369018</pub-id>
</element-citation></ref><ref id="B126-pharmaceutics-17-00148"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akdag</surname><given-names>Y.</given-names></name>
<name><surname>Gulsun</surname><given-names>T.</given-names></name>
<name><surname>Izat</surname><given-names>N.</given-names></name>
<name><surname>Cetin</surname><given-names>M.</given-names></name>
<name><surname>Oner</surname><given-names>L.</given-names></name>
<name><surname>Sahin</surname><given-names>S.</given-names></name>
</person-group><article-title>Evaluation of Preparation Methods for Orally Disintegrating Tablets</article-title><source>Medicine</source><year>2020</year><volume>9</volume><fpage>259</fpage><pub-id pub-id-type="doi">10.5455/medscience.2019.08.9167</pub-id></element-citation></ref><ref id="B127-pharmaceutics-17-00148"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mishra</surname><given-names>D.N.</given-names></name>
<name><surname>Bindal</surname><given-names>M.</given-names></name>
<name><surname>Singh</surname><given-names>S.K.</given-names></name>
<name><surname>Vijaya Kumar</surname><given-names>S.G.</given-names></name>
</person-group><article-title>Spray Dried Excipient Base: A Novel Technique for the Formulation of Orally Disintegrating Tablets</article-title><source>Chem. Pharm. Bull.</source><year>2006</year><volume>54</volume><fpage>99</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1248/cpb.54.99</pub-id><pub-id pub-id-type="pmid">16394558</pub-id>
</element-citation></ref><ref id="B128-pharmaceutics-17-00148"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toor</surname><given-names>R.</given-names></name>
<name><surname>Kumari</surname><given-names>B.</given-names></name>
</person-group><article-title>New technologies in the formulation of oral dispersible tablets and taste masking: A review</article-title><source>Indian Res. J. Pharm. Sci.</source><year>2018</year><volume>5</volume><fpage>1288</fpage><lpage>1301</lpage><pub-id pub-id-type="doi">10.21276/irjps.2018.5.1.7</pub-id></element-citation></ref><ref id="B129-pharmaceutics-17-00148"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allahham</surname><given-names>N.</given-names></name>
<name><surname>Fina</surname><given-names>F.</given-names></name>
<name><surname>Marcuta</surname><given-names>C.</given-names></name>
<name><surname>Kraschew</surname><given-names>L.</given-names></name>
<name><surname>Mohr</surname><given-names>W.</given-names></name>
<name><surname>Gaisford</surname><given-names>S.</given-names></name>
<name><surname>Basit</surname><given-names>A.W.</given-names></name>
<name><surname>Goyanes</surname><given-names>A.</given-names></name>
</person-group><article-title>Selective Laser Sintering 3D Printing of Orally Disintegrating Printlets Containing Ondansetron</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>110</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12020110</pub-id><pub-id pub-id-type="pmid">32019101</pub-id>
</element-citation></ref><ref id="B130-pharmaceutics-17-00148"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pyteraf</surname><given-names>J.</given-names></name>
<name><surname>Jamr&#x000f3;z</surname><given-names>W.</given-names></name>
<name><surname>Kurek</surname><given-names>M.</given-names></name>
<name><surname>B&#x00105;k</surname><given-names>U.</given-names></name>
<name><surname>Loskot</surname><given-names>J.</given-names></name>
<name><surname>Kramarczyk</surname><given-names>D.</given-names></name>
<name><surname>Paluch</surname><given-names>M.</given-names></name>
<name><surname>Jachowicz</surname><given-names>R.</given-names></name>
</person-group><article-title>Preparation and Advanced Characterization of Highly Drug-Loaded, 3D Printed Orodispersible Tablets Containing Fluconazole</article-title><source>Int. J. Pharm.</source><year>2023</year><volume>630</volume><fpage>122444</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.122444</pub-id><pub-id pub-id-type="pmid">36503848</pub-id>
</element-citation></ref><ref id="B131-pharmaceutics-17-00148"><label>131.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>West</surname><given-names>T.G.</given-names></name>
<name><surname>Bradbury</surname><given-names>T.J.</given-names></name>
</person-group><article-title>3D Printing: A Case of ZipDose&#x000ae; Technology&#x02014;World&#x02019;s First 3D Printing Platform to Obtain FDA Approval for a Pharmaceutical Product</article-title><source>3D and 4D Printing in Biomedical Applications</source><publisher-name>John Wiley &#x00026; Sons, Ltd.</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2019</year><fpage>53</fpage><lpage>79</lpage><isbn>978-3-527-81370-4</isbn></element-citation></ref><ref id="B132-pharmaceutics-17-00148"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jaipal</surname><given-names>A.</given-names></name>
<name><surname>Pandey</surname><given-names>M.M.</given-names></name>
<name><surname>Charde</surname><given-names>S.Y.</given-names></name>
<name><surname>Sadhu</surname><given-names>N.</given-names></name>
<name><surname>Srinivas</surname><given-names>A.</given-names></name>
<name><surname>Prasad</surname><given-names>R.G.</given-names></name>
</person-group><article-title>Controlled Release Effervescent Buccal Discs of Buspirone Hydrochloride: In Vitro and in Vivo Evaluation Studies</article-title><source>Drug Deliv.</source><year>2016</year><volume>23</volume><fpage>452</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.3109/10717544.2014.917388</pub-id><pub-id pub-id-type="pmid">24892624</pub-id>
</element-citation></ref><ref id="B133-pharmaceutics-17-00148"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yildir</surname><given-names>E.</given-names></name>
<name><surname>Sj&#x000f6;holm</surname><given-names>E.</given-names></name>
<name><surname>Preis</surname><given-names>M.</given-names></name>
<name><surname>Trivedi</surname><given-names>P.</given-names></name>
<name><surname>Trygg</surname><given-names>J.</given-names></name>
<name><surname>Fardim</surname><given-names>P.</given-names></name>
<name><surname>Sandler</surname><given-names>N.</given-names></name>
</person-group><article-title>Investigation of Dissolved Cellulose in Development of Buccal Discs for Oromucosal Drug Delivery</article-title><source>Pharm. Dev. Technol.</source><year>2018</year><volume>23</volume><fpage>520</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1080/10837450.2017.1397163</pub-id><pub-id pub-id-type="pmid">29067849</pub-id>
</element-citation></ref><ref id="B134-pharmaceutics-17-00148"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dhiman</surname><given-names>S.</given-names></name>
<name><surname>Bhatt</surname><given-names>S.</given-names></name>
<name><surname>Mannan</surname><given-names>A.</given-names></name>
<name><surname>Arora</surname><given-names>S.</given-names></name>
<name><surname>Singh</surname><given-names>T.G.</given-names></name>
</person-group><article-title>Formulation and Characterization of Zaleplon Buccal Disks Using Grafted Moringa Oleifera Gum</article-title><source>J. App. Pharm. Sci.</source><year>2023</year><volume>13</volume><fpage>115</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.7324/JAPS.2023.130111</pub-id></element-citation></ref><ref id="B135-pharmaceutics-17-00148"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shahadha</surname><given-names>R.</given-names></name>
<name><surname>Maraie</surname><given-names>N.</given-names></name>
</person-group><article-title>Mucoadhesive Film Forming Spray for Buccal Drug Delivery: A Review</article-title><source>Al Mustansiriyah J. Pharm. Sci.</source><year>2023</year><volume>23</volume><fpage>105</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.32947/ajps.v23i1.994</pub-id></element-citation></ref><ref id="B136-pharmaceutics-17-00148"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palermo</surname><given-names>A.</given-names></name>
<name><surname>Maddaloni</surname><given-names>E.</given-names></name>
<name><surname>Pozzilli</surname><given-names>P.</given-names></name>
</person-group><article-title>Buccal Spray Insulin (Oralgen) for Type 2 Diabetes: What Evidence?</article-title><source>Expert Opin. Biol. Ther.</source><year>2012</year><volume>12</volume><fpage>767</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1517/14712598.2012.675324</pub-id><pub-id pub-id-type="pmid">22515262</pub-id>
</element-citation></ref><ref id="B137-pharmaceutics-17-00148"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>H.B.</given-names></name>
<name><surname>Huang</surname><given-names>K.X.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.S.</given-names></name>
<name><surname>Gao</surname><given-names>Q.H.</given-names></name>
<name><surname>Wu</surname><given-names>Q.Z.</given-names></name>
<name><surname>Tian</surname><given-names>W.Q.</given-names></name>
<name><surname>Sheng</surname><given-names>X.Q.</given-names></name>
<name><surname>Chen</surname><given-names>Z.X.</given-names></name>
<name><surname>Gao</surname><given-names>Z.H.</given-names></name>
</person-group><article-title>Hypoglycaemic Effect of a Novel Insulin Buccal Formulation on Rabbits</article-title><source>Pharmacol. Res.</source><year>2002</year><volume>46</volume><fpage>459</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/S1043661802002049</pub-id><pub-id pub-id-type="pmid">12419651</pub-id>
</element-citation></ref><ref id="B138-pharmaceutics-17-00148"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Modi</surname><given-names>P.</given-names></name>
<name><surname>Mihic</surname><given-names>M.</given-names></name>
<name><surname>Lewin</surname><given-names>A.</given-names></name>
</person-group><article-title>The Evolving Role of Oral Insulin in the Treatment of Diabetes Using a Novel RapidMist System</article-title><source>Diabetes Metab. Res. Rev.</source><year>2002</year><volume>18</volume><issue>(Suppl. S1)</issue><fpage>S38</fpage><lpage>S42</lpage><pub-id pub-id-type="doi">10.1002/dmrr.208</pub-id><pub-id pub-id-type="pmid">11921428</pub-id>
</element-citation></ref><ref id="B139-pharmaceutics-17-00148"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trincado</surname><given-names>V.</given-names></name>
<name><surname>Gala</surname><given-names>R.P.</given-names></name>
<name><surname>Morales</surname><given-names>J.O.</given-names></name>
</person-group><article-title>Buccal and Sublingual Vaccines: A Review on Oral Mucosal Immunization and Delivery Systems</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1177</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9101177</pub-id><pub-id pub-id-type="pmid">34696284</pub-id>
</element-citation></ref><ref id="B140-pharmaceutics-17-00148"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Modi</surname><given-names>A.</given-names></name>
<name><surname>Sanal</surname><given-names>R.</given-names></name>
<name><surname>Suresh</surname><given-names>A.</given-names></name>
<name><surname>Saraswathy</surname><given-names>M.</given-names></name>
</person-group><article-title>Enhanced Mucoadhesive Properties of Ionically Cross-Linked Thiolated Gellan Gum Films</article-title><source>J. Biomater. Sci. Polym. Ed.</source><year>2024</year><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1080/09205063.2024.2397199</pub-id></element-citation></ref><ref id="B141-pharmaceutics-17-00148"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shahidulla</surname><given-names>D.</given-names></name>
<name><surname>Begum</surname><given-names>A.</given-names></name>
<name><surname>Fatima</surname><given-names>A.</given-names></name>
</person-group><article-title>Buccal film: An updated overview</article-title><source>Int. J. Innov. Res. Multidiscipl. Field</source><year>2022</year><volume>8</volume><fpage>132</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.2015/ijirmf/202211023</pub-id></element-citation></ref><ref id="B142-pharmaceutics-17-00148"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shipp</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Kerai-Varsani</surname><given-names>L.</given-names></name>
<name><surname>Okwuosa</surname><given-names>T.C.</given-names></name>
</person-group><article-title>Buccal Films: A Review of Therapeutic Opportunities, Formulations &#x00026; Relevant Evaluation Approaches</article-title><source>J. Control. Release</source><year>2022</year><volume>352</volume><fpage>1071</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.10.058</pub-id><pub-id pub-id-type="pmid">36351519</pub-id>
</element-citation></ref><ref id="B143-pharmaceutics-17-00148"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patil</surname><given-names>H.</given-names></name>
<name><surname>Vemula</surname><given-names>S.K.</given-names></name>
<name><surname>Narala</surname><given-names>S.</given-names></name>
<name><surname>Lakkala</surname><given-names>P.</given-names></name>
<name><surname>Munnangi</surname><given-names>S.R.</given-names></name>
<name><surname>Narala</surname><given-names>N.</given-names></name>
<name><surname>Jara</surname><given-names>M.O.</given-names></name>
<name><surname>Williams</surname><given-names>R.O.</given-names></name>
<name><surname>Terefe</surname><given-names>H.</given-names></name>
<name><surname>Repka</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Hot-Melt Extrusion: From Theory to Application in Pharmaceutical Formulation&#x02014;Where Are We Now?</article-title><source>AAPS PharmSciTech</source><year>2024</year><volume>25</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.1208/s12249-024-02749-2</pub-id><pub-id pub-id-type="pmid">38355916</pub-id>
</element-citation></ref><ref id="B144-pharmaceutics-17-00148"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brandl</surname><given-names>M.</given-names></name>
<name><surname>Bauer-Brandl</surname><given-names>A.</given-names></name>
</person-group><article-title>Oromucosal Drug Delivery: Trends in in-Vitro Biopharmaceutical Assessment of New Chemical Entities and Formulations</article-title><source>Eur. J. Pharm. Sci.</source><year>2019</year><volume>128</volume><fpage>112</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2018.11.031</pub-id><pub-id pub-id-type="pmid">30502454</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00148-f001"><label>Figure 1</label><caption><p>The main anatomical regions of the oral cavity play the most important role in basic functions and medication through the oral mucosa.</p></caption><graphic xlink:href="pharmaceutics-17-00148-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00148-f002"><label>Figure 2</label><caption><p>Visual overview of the formulation possibilities of ODT preparations. The various technological processes ensure the fastest disintegration in the minimum liquid medium.</p></caption><graphic xlink:href="pharmaceutics-17-00148-g002" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00148-t001"><object-id pub-id-type="pii">pharmaceutics-17-00148-t001_Table 1</object-id><label>Table 1</label><caption><p>Comparison of different gastrointestinal secretions [<xref rid="B32-pharmaceutics-17-00148" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00148" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-17-00148" ref-type="bibr">34</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Volume (Mean)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">pH</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Enzyme Activity</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Saliva</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1 mL</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5&#x02013;7</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gastric fluid</td><td align="center" valign="middle" rowspan="1" colspan="1">45&#x02013;686 mL</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9&#x02013;5.4</td><td align="center" valign="middle" rowspan="1" colspan="1">High</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Intestinal fluid</td><td align="center" valign="middle" rowspan="1" colspan="1">54&#x02013;105 mL</td><td align="center" valign="middle" rowspan="1" colspan="1">6.8&#x02013;7.2</td><td align="center" valign="middle" rowspan="1" colspan="1">High</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rectal fluid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;3 mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7&#x02013;8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00148-t002"><object-id pub-id-type="pii">pharmaceutics-17-00148-t002_Table 2</object-id><label>Table 2</label><caption><p>Comparison of permeability from the skin and the oral mucosa regions, adapted from Lesch et al. [<xref rid="B37-pharmaceutics-17-00148" ref-type="bibr">37</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Region</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Permeability Constant (Kp (&#x000d7;10<sup>&#x02212;7</sup> &#x000b1; SEM cm/min))</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Skin</td><td align="center" valign="middle" rowspan="1" colspan="1">44 &#x000b1; 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hard palate</td><td align="center" valign="middle" rowspan="1" colspan="1">470 &#x000b1; 27</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Buccal mucosa</td><td align="center" valign="middle" rowspan="1" colspan="1">579 &#x000b1; 16</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lateral border of tongue</td><td align="center" valign="middle" rowspan="1" colspan="1">772 &#x000b1; 23</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Floor of mouth</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">973 &#x000b1; 33</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00148-t003"><object-id pub-id-type="pii">pharmaceutics-17-00148-t003_Table 3</object-id><label>Table 3</label><caption><p>Options for bioavailability enhancement in oral cavity I.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Method</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Advantage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disadvantage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Literature</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucoadhesion</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Easy use</p></list-item><list-item><label>-</label><p>Low toxicity</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Limited absorption capacity</p></list-item><list-item><label>-</label><p>Circumstances like pH can affect release</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-pharmaceutics-17-00148" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-17-00148" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-17-00148" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Penetration enhancement</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Inert, non-toxic materials</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Possible irritation and alteration of stability</p></list-item><list-item><label>-</label><p>Unpleasant sensory properties</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-pharmaceutics-17-00148" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-17-00148" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fast disintegration</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Immediate release&#x02014;easy administration</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Stability concerns</p></list-item><list-item><label>-</label><p>Complicated production</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-pharmaceutics-17-00148" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceutics-17-00148" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceutics-17-00148" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-17-00148" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enzyme inhibition</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Higher pharmacon stability</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Potential side effects of excipients</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-pharmaceutics-17-00148" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-17-00148" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceutics-17-00148" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prodrug</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Targeted delivery</p></list-item><list-item><label>-</label><p>Improved pharmacokinetics</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Delayed effect and possible toxic metabolites</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-pharmaceutics-17-00148" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceutics-17-00148" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceutics-17-00148" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoparticles</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Sustained release</p></list-item><list-item><label>-</label><p>Reduced irritation</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Manufacturing challenges</p></list-item><list-item><label>-</label><p>Possibility of toxicity and bioaccumulation</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-pharmaceutics-17-00148" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceutics-17-00148" ref-type="bibr">59</xref>,<xref rid="B60-pharmaceutics-17-00148" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-17-00148" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modifying lipophilicity</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Enhanced cellular uptake</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Solubility concerns</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-pharmaceutics-17-00148" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceutics-17-00148" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-17-00148" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Biocompatibility</p></list-item><list-item><label>-</label><p>Enhanced membrane penetration</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Higher production costs</p></list-item><list-item><label>-</label><p>Large-scale production problems</p></list-item><list-item><label>-</label><p>Stability issues</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-pharmaceutics-17-00148" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceutics-17-00148" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceutics-17-00148" ref-type="bibr">67</xref>,<xref rid="B68-pharmaceutics-17-00148" ref-type="bibr">68</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00148-t004"><object-id pub-id-type="pii">pharmaceutics-17-00148-t004_Table 4</object-id><label>Table 4</label><caption><p>Options for bioavailability enhancement in oral cavity II.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Method</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Common Excipients</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pharmacon Examples</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Literature</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucoadhesion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyacrylic acid, carboxymethyl-cellulose, chitosan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fentanyl, miconazole, theophylline, dexamethasone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-pharmaceutics-17-00148" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-17-00148" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-17-00148" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Penetration enhancement</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium deoxycholate, sodium myristate, cyclodextrin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insulin, other peptides</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-pharmaceutics-17-00148" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-17-00148" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fast disintegration</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microcrystalline cellulose, camphor, mannitol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Propranolol, metformin, ibuprofen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-pharmaceutics-17-00148" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceutics-17-00148" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceutics-17-00148" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-17-00148" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enzyme inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aprotinin, bestatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insulin, calcitonin, thymopentin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-pharmaceutics-17-00148" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-17-00148" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceutics-17-00148" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">prodrug</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">isoniazid, levodopa, morphine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-pharmaceutics-17-00148" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceutics-17-00148" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceutics-17-00148" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polystyrene, pullulan, chitosan, hydroxypropyl methylcellulose, oleic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tedizolid, repaglinide, dexamethasone, leuprolide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-pharmaceutics-17-00148" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceutics-17-00148" ref-type="bibr">59</xref>,<xref rid="B60-pharmaceutics-17-00148" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-17-00148" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modifying lipophilicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyethylene glycol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Warfarin, naproxen, verapamil, lidocaine, progesterone, cyclosporine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-pharmaceutics-17-00148" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceutics-17-00148" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-17-00148" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phosphatidylcholine, cholesterol, soybean lecithin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Resveratrol, calcitonin, efavirenz</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-pharmaceutics-17-00148" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceutics-17-00148" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceutics-17-00148" ref-type="bibr">67</xref>,<xref rid="B68-pharmaceutics-17-00148" ref-type="bibr">68</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>